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CHAPTER 1 
Introduction 
The human pain experience, both experimental and clinical, is composed of three 
dimensions (Gracely, McGrath, & Dubner, 1978; Price, Harkins, & Baker, 1987).  The 
sensory-discriminative dimension of pain permits the individual to localize the painful 
stimulus, and to assess its intensity and physical properties.  The affective-motivational 
dimension encourages avoidance and recuperation via the perception of negative affect 
associated with noxious stimulation.  The cognitive-evaluative dimension induces an 
appraisal of the meanings and consequences associated with painful sensations and 
injury.  These latter two dimensions interact to generate emotional disturbances such as 
fear, anxiety, frustration and depression that contribute to the suffering and physical 
disabilities of patients in chronic pain (Crombez, Vlaeyen, Heuts, & Lysens, 1999; 
McCracken, Zayfert, & Gross, 1992; Sullivan, Reesor, Mikail, & Fisher, 1992; Waddell, 
Newton, Henderson, Somerville, & Main, 1993; Wade, Dougherty, Hart, Rafii, & Price, 
1992).  Therefore, understanding the neurobiology that underlies the generation and 
suppression of pain affect is of clinical importance and warrants intensive study.   
The amygdala is a forebrain structure critical for providing affective salience to 
sensory information for animals and humans (LeDoux, 2000).  Functional magnetic 
resonance imaging studies in humans report that increased amygdala activation is 
associated with fear and anxiety (Adolphs, Tranel, & Damasio, 1998; Critchley, Mathias, 
& Dolan, 2002; Furmark, Fischer, Wik, Larsson, & Fredrikson, 1997; Tillfors, et al., 
2001) or exposure to threatening stimuli (Carlsson, et al., 2004; Carretie, Hinojosa, 
Mercado, & Tapia, 2005; Isenberg, et al., 1999; Phelps, et al., 2001).  Similarly, 
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amygdala activation is observed in fearful and anxious rats, or in rats exposed to 
aversive and threatening stimuli (Adell, Casanovas, & Artigas, 1997; Duncan, Knapp, & 
Breese, 1996; Figueiredo, Bodie, Tauchi, Dolgas, & Herman, 2003; Lehner, et al., 
2006).  On the other hand, damage to the amygdala suppresses responding to aversive 
and threatening stimuli in both humans and animals (Blanchard & Blanchard, 1972; 
Borszcz & Leaton, 2003; Hebben, Corkin, Eichenbaum, & Shedlack, 1985; Jelasic, 
1966).  These findings indicate that the amygdala acts as the “threat detector” of the 
brain.  The amygdala processes stimuli that threaten the individual and contributes to 
the execution of affective behaviors that permit the individual to cope with the threat 
(Bernard & Bandler, 1998; LeDoux, 2000).   
The prototypical threat to an individual is exposure to a noxious stimulus  Within the 
brain, the amygdaloid central nucleus (CeA) and basolateral complex (BLC; includes 
lateral and basolateral subnuclei) receive nociceptive afferents via spinoamygdaloid 
(Giesler, Katter, & Dado, 1994; Newman, Stevens, & Apkarian, 1996) and spino-
parabrachio-amygdaloid pathways (Bernard & Besson, 1990; Ma & Peschanski, 1988), 
directly from collaterals of the spinothalamic tract (Burstein & Potrebic, 1993), and 
indirectly from spinoreticulothalamic and spinopontothalamic tracts via inputs relayed by 
medial and intralaminar thalamic nuclei (Bourgeais, Gauriau, & Bernard, 2001; Krout & 
Loewy, 2000; Petrovicky, 1990; Su & Bentivoglio, 1990; Volz, et al., 1990), and the 
insular cortex (Shi & Davis, 1999).  Noxious stimulation evokes neural activity in both 
CeA and BLC (Bernard, Huang, & Besson, 1990; Romanski, Clugnet, Bordi, & LeDoux, 
1993).   
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In addition to nociceptive input, the BLC receives highly processed multimodal 
sensory information from several cortical regions (visual, auditory, somatosensory and 
olfactory cortices), as well as more direct but less processed sensory information from 
the corresponding thalamic nuclei.  The BLC is proposed to process these inputs and 
allocate emotional salience to those that represent environmental threats.  The outputs 
of the BLC engage the defense circuit that enables the individual to respond to the 
threat (McDonald, 1998; Pitkanen, 2000).  The CeA is the major output sub-nucleus of 
the amygdala and the CeA receives afferents from the BLC.  Efferents from CeA to the 
hypothalamus, periaqueductal gray, and medulla coordinate execution of defensive 
behaviors designed to cope with threats (LeDoux, Iwata, Cicchetti, & Reis, 1988; 
Petrovich, Canteras, & Swanson, 2001; Pitkanen, 2000).  Therefore, the CeA was 
evaluated for its contribution to the production of pain affect in the present study. 
1.1 Evidence for a Role of the Amygdala in Pain Processing 
 Case studies of patients that received ablations within the limbic forebrain 
implicate the amygdala as an essential structure involved in the affective experience of 
pain.  The classic neurological patient H.M. received a bilateral resection of the medial 
temporal lobe for the treatment of epilepsy, resulting in the ablation of several limbic 
structures, including most of the amygdaloid complex (Corkin, Amaral, Gonzalez, 
Johnson, & Hyman, 1997).  H.M. subsequently suffered from a range of neurological 
deficits, including anterograde amnesia, the inability to perceive odor quality, and most 
relevant to the current investigation, the failure to identify painful stimuli and to withdraw 
from such stimuli (Corkin, 1984; Hebben, et al., 1985). Hebben and colleagues (1985) 
demonstrated that thermal stimulation of H.M.’s hand or chest, as compared to normal 
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control patients and control patients with global amnesia, resulted in a failure to 
perceive the stimulation as noxious as measured by withdrawal latency (Hebben, et al., 
1985).  Although these results implicate the ablated region (i.e., amygdala) in pain 
sensation, H.M.’s inability to report internal states such as hunger and thirst and his 
inability to feel discomfort from the applied noxious thermal stimulation suggests a 
generalized deficit in affective responding.   
In patients with trigeminal neuralgia, bilateral amygdalotomy reduces intractable 
pain (Jelasic, 1966).  Patients reported moderate to intense pain during electrode 
implantation and during injection of the lesioning material into the left or right 
hemispheric amygdala.  Following the procedure, patients reported decreased pain 
sensation and decreased pain affect to the neuralgia syndrome.  Brown (1977) 
successfully treated intractable pain patients who experienced associated psychological 
consequences (e.g., drug dependence and psychogenic fixation) with lesions of the 
limbic system (Brown, 1977).  Follow-up assessments of up to twenty years revealed 
that the majority of patients (90.5%) experienced improvement as measured by pain 
relief, requirement of medication, and ability to function at a job or in the home.  These 
case studies demonstrate that the amygdala and other forebrain structures process 
nociceptive information, and most notably, mediate the affective dimension of the pain 
experience. 
In accordance with the findings from lesion studies, human neuroimaging studies 
consistently reveal activation of the amygdala during noxious stimulation (Bingel, et al., 
2002; Kulkarni, et al., 2005).  Bingel and colleagues (2002) reported that application of 
noxious radiant stimuli via a thulium (Tm)-yttrium-aluminum-granate (YAG) laser to 
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either the left or right hand of healthy participants evoked bilateral increases in the 
blood-oxygen-level-dependence (BOLD) measure within the amygdala.  Bilateral 
activation of the amygdala to a unilateral stimulus precludes amygdalar involvement in 
the sensory-discriminative aspect of pain processing and rather supports a role of the 
amygdala in the affective-motivational aspect of pain processing.  Further, healthy 
participants instructed to attend to the unpleasantness associated with the application of 
a noxious CO2 laser to the left dorsal forearm exhibited increases in regional cerebral 
blood flow (rCBF) within the amygdala (Kulkarni, et al., 2005).  Participants instructed to 
attend to the location of the stimulus did exhibit a change in rCBF levels within the 
amygdala.  These results support the notion that the amygdala is involved in affective-
motivational processing of nociceptive information.  It should be noted that the 
resolution of current imaging technology does not permit identification of the individual 
amygdaloid nuclei activated in these studies.  Recently, however, pain-evoked neural 
activity was recorded in humans through electrodes implanted bilaterally in the medial 
temporal lobe during the investigation of intractable epilepsy (Liu, et al., 2010).  
Stimulation of the hand with a laser that selectively activated cutaneous nociceptors 
produced evoked responses from CeA.  Consistent with the results of neuroimaging 
studies, pain-evoked responses in CeA were recorded bilaterally following stimulation of 
either hand. 
Fos is the protein product encoded by the c-Fos gene that is expressed following 
neurotransmitter binding and membrane depolarization (Sheng & Greenberg, 1990), 
and provides an indirect measure of neuronal activation.  Fos expression is increased in 
the amygdaloid complex following acute intra-plantar (i.pl.) formalin injection (Lei, 
 
6 
Zhang, & Zhao, 2004) and in response to noxious peripheral stimulation of the tail via 
hot water bath (Dai, Zhu, Li, Huang, & Xu, 1993).  These studies do not discuss which 
subnuclei of the amygdala exhibited increased Fos expression, however, examination of 
the histological figures suggest primary labeling in the medial, lateral, basal, and central 
nuclei.  Nakagawa and colleagues (2003) reported that i.pl. formalin injections 
significantly increased Fos expression in the lateral and basolateral amygdala, but not 
CeA, contralateral to the side of stimulus presentation.  However, these investigators 
observed that intraperitoneal (i.p.) administration of acetic acid elevated Fos expression 
in CeA, and to a lesser degree in LA and BLA (Nakagawa, et al., 2003). Fear 
conditioning studies that utilize noxious foot-shock as an unconditional stimulus (US) 
revealed that foot-shock administered within a context during training results in 
increased CeA-Fos expression when compared to rats that did not receive foot-shock 
within that same context (Milanovic, et al., 1998; Radulovic, Kammermeier, & Spiess, 
1998).  Deep somatic pain induced by formalin injection into the rat multifidus muscle 
(i.e., low back muscle) produces significant Fos expression in the BLA (Ohtori, et al., 
2000).  The pharmacological activation of protein kinase C (PKC), via intrathecal 
phorbol 12,13-dibutyrate administration, within the spinal dorsal horn produces 
behavioral pain states (i.e., scratching, licking, biting, severe tail shaking, and 
vocalizations), and these nociceptive behaviors correlate with Fos expression in the 
cingulate cortex, parafascicular nucleus, and basolateral amygdala (Narita, et al., 2004).  
That cellular activation of the amygdala arises from such a diverse typology of noxious 
stimulation implicates the amygdala as a structure strongly involved in the experience of 
pain. 
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Excitotoxic lesions of CeA resulted in the abolition of conditioned place aversion 
(CPA) supported by noxious chemical stimulation (i.p. administered acetic acid) or 
formalin injection into the hind-paw, but failed to reduce associated nociceptive 
behaviors (Tanimoto, Nakagawa, Yamauchi, Minami, & Satoh, 2003).  Acetic acid-
induced pain behaviors included typical writhing behavior (i.e., contraction of abdominal 
muscles followed by extension of the hind limbs) and formalin-induced pain behaviors 
included the elevation and the biting, licking, or shaking of the injected paw.  These 
results suggest a role of CeA in the generation of pain affect as measured by CPA, but 
not pain sensation as measured by the aforementioned writhing and formalin-induced 
pain behaviors.  Because the forebrain does not integrate writhing behavior or formalin 
behavior (Hammond, 1989; Matthies & Franklin, 1992), amygdalar lesions would not 
affect these behaviors.  Additionally, electrolytic lesions of the CeA resulted in the 
elevation of the threshold for tail-shock to elicit the vocalization after-discharge (VAD) 
response (Borszcz & Leaton, 2003).  Research in this laboratory validated VADs as a 
model of pain affect (Borszcz, 1993, 1995a, 1995b; Borszcz, Johnson, & Fahey, 1994).  
These vocalizations occur following a brief noxious tail-shock and are spectrographically 
distinct from vocalizations that occur during tail-shock (VDS; Borszcz, 1995b, 2006).  
This evidence that amygdala lesions suppress affective pain responses strongly 
implicates the amygdala in the processing of the affective-motivational dimension of the 
pain experience. 
1.2 Nociceptive Processing within CeA: Contribution of Glutamate Receptors 
As described earlier, the CeA receives nociceptive afferents via a variety of 
pathways.  In the rat, nociceptively responsive neurons in CeA are localized within the 
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lateral capsular sub-division (CeALC).  CeALC neurons have either wide dynamic range 
(WDR) or nociceptive specific (NS) characteristics (Bird, et al., 2005; Han & 
Neugebauer, 2005; Li & Neugebauer, 2004a, 2004b).  WDR neurons respond to both 
innocuous and noxious stimulation of the periphery with the rate of neural activity 
related to intensity of stimulation, and NS neurons respond only to noxious stimulation.  
Activation of both WDR and NS neurons occurs following stimulation of broad areas of 
the body, indicating large receptive fields for both types of neuron (Bernard & Besson, 
1990; Bernard, Huang, & Besson, 1992; Neugebauer & Li, 2002).   
Nociceptive input to NS neurons in CeALC appears to be provided by the spino-
parabrachio-amygdaloid pathway (Bernard & Besson, 1990; Ma & Peschanski, 1988).  
Nociceptively responsive neurons in the external lateral pontine parabrachial (pPBel) 
and external medial pontine parabrachial (pPBem) nuclei that project to CeALC are 
innervated by projections from nociceptively responsive laminae I neurons of the spinal 
dorsal horn (Todd, et al., 2002).  These PB neurons lack WDR characteristics, and only 
respond to noxious input from the periphery (i.e., possess NS characteristics; Bernard & 
Besson, 1990). 
 Noxious-evoked activity in WDR neurons in CeALC is mediated by glutamate 
receptors.  Li and Neugebauer (2004a) recorded extracellular single-unit activity from 
WDR neurons in CeALC in anesthetized rats.  The neurons’ responses to graded brief 
(15 s) mechanical stimuli (noxious pinch) applied to the knee were challenged by 
administration of NMDA (APV) and non-NMDA (DNQX) receptor antagonists into the 
CeA via reverse microdialysis.  Both receptor antagonists suppressed noxious-evoked 
neural activity in CeALC.  APV failed to alter spontaneous background activity or the 
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response of CeALC neurons to innocuous mechanical stimulation.  Alternately, DNQX 
also suppressed background activity and the response of CeALC neurons to innocuous 
stimulation. 
 Given the contribution of the CeA to the production of affective behaviors in 
response to threats, and the contribution of CeA-glutamate receptors to nociceptive 
processing within the CeA, we evaluated the effects of CeA-administration of NMDA 
and non-NMDA receptor antagonists on the generation of pain affect.  We observed that 
administration of APV (NMDA antagonist) or CNQX (non-NMDA antagonist) into the 
CeA preferentially elevated the current intensity of tail-shock to elicit VADs (Spuz & 
Borszcz, in preparation; see Figure 1 for APV data).  The current intensity to elicit VDS 
was elevated to a lesser degree; whereas, the current to elicit spinal motor reflexes 
(SMRs = tail-flicks) was not altered by injection of glutamate receptor antagonists into 
the CeA.  These findings indicate that glutamate-mediated neuronal activation in CeA 
contributes preferentially to the production of the affective response to pain.    
1.3 Evidence for the Involvement of NMDA Receptors within the Amygdaloid Central 
Nucleus in Antinociception 
Whereas the aforementioned results indicate that NMDA (and non-NMDA) receptor-
mediated neuronal excitation within CeA contributes to production of pain affect, a 
variety of evidence indicates that activation of the CeA suppresses responses to 
noxious stimulation.  Electrical stimulation of the CeA results in antinociception 
measured as an increase in the tail-flick latency to noxious heating of the tail (Mena, 
Mathur, & Nayar, 1995; Oliveira & Prado, 1998), a reduction of the tonic phase in the 
formalin test and suppression of VDSs and VADs to noxious tail-shock  (Mena, et al., 
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1995).  Additionally, stimulation of the CeA suppresses shock-induced vocalizations in 
guinea pigs (Leite-Panissi, Coimbra, & Menescal-de-Oliveira, 2003).    
As systemic administration of NMDA agonists produces neuronal excitation within 
CeA (Inada, Farrington, Moy, Koller, & Duncan, 2007; Radulovic, Blank, Nijholt, 
Kammermeier, & Spiess, 2000) the possibility that NMDA receptor agonism within CeA 
(like NMDA receptor antagonism) suppresses pain affect was evaluated.  Preliminary 
findings demonstrated that administration of NMDA into the CeA produced 
antinociceptive effects similar to that observed following injection of APV into the CeA 
(see Figure 2).  That is, both treatments preferentially elevated VAD threshold.  The 
present study was designed to evaluate the mechanisms through which NMDA receptor 
activation and antagonism within CeA produce suppression of pain affect. 
Hypothesis 
The central hypothesis of this study is that NMDA receptor antagonism within CeA 
blocks nociceptive transmission to efferent sites of CeA that coordinate affective 
responding to noxious stimulation; whereas, NMDA receptor activation within CeA 
engages efferent projections of CeA that activate endogenous antinociceptive 
mechanisms that suppress nociceptive transmission that contributes to production of 
pain affect. Support for the former mechanism is provided by the aforementioned 
findings that administration of an NMDA receptor antagonist into the CeA inhibits 
noxious evoked neuronal activity within CeA (Li & Neugebauer, 2004a), and our finding 
that administration of APV into the CeA suppresses pain-induced vocalizations  The 
latter mechanism is supported by reports that antinociception elicited by stimulation of 
CeA is blocked by inactivation of the ventrolateral periaqueductal gray (vlPAG; Leite-
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Panissi, et al., 2003; Oliveira & Prado, 1998).  The vlPAG is a core mesencephalic 
structure that contributes to opiate-induced antinociception (Bodnar, Williams, Lee, & 
Pasternak, 1988; Borszcz, 1995a; Borszcz, Johnson, & Thorp, 1996; Jensen & Yaksh, 
1986), and is reciprocally interconnected with CeA (Mantyh, 1982, 1983a, 1983b).  
Electrical stimulation of the CeA produces antinociception that is blocked by 
pretreatment of the vlPAG with the mu-opioid receptor antagonist beta-funaltrexamine 
(Oliveira & Prado, 2001). Moreover, glutamatergic stimulation of CeA activates 
projection neurons in vlPAG through enkephalin-mediated disinhibition (Behbehani, 
Jiang, & Chandler, 1990; da Costa Gomez & Behbehani, 1995; Sandkuhler, Willmann, 
& Fu, 1989).  Projections of these vlPAG neurons to limbic, thalamic and brainstem 
sites contribute to the suppression of pain affect elicited by morphine injected into 
vlPAG (Borszcz, 1995a, 1999).  
Specific Aims  
Based on preliminary findings, the specific aims of this study were as follows:  
Aim #1:  Complete the evaluation of the suppression of pain affect produced by  
          administration of NMDA into the CeA.  
 Anatomical specificity: It was hypothesized that administration of NMDA 
into sites surrounding CeA will be less effective in suppressing VADs 
compared to administration into the CeA.  
 Neurotoxicity: It was hypothesized that histological evaluation of CeA will 
reveal that NMDA-mediated suppression of VADs is not related to NMDA-
induced neurotoxicity.  
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Aim #2:  Evaluate the functional interaction between the CeA and vlPAG in the  
  suppression of pain affect.  
 It was hypothesized that if intra-CeA NMDA administration generates 
antinociception through activation of enkephalinergic interneurons in 
vlPAG, then suppression of VADs observed with intra-CeA NMDA 
administration will be attenuated or abolished following the intra-vlPAG 
administration of an enkephalin antagonist.  
Aim #3:  Evaluate the cellular response of the vlPAG to NMDA and NMDA   
  antagonist administered into the CeA.  
 It was hypothesized that if NMDA receptor antagonism blocks the through-
put of nociceptive transmission at the level of the CeA, and if NMDA 
receptor agonism activates neural projections involved in endogenous 
antinociception, then the expression of the neural activity marker Fos 
within the endogenous antinociceptive circuit will differ following intra-CeA 
NMDA receptor antagonist vs. agonist.  
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CHAPTER 2 
Methods 
2.1 General Methods 
Animals 
A total of ninety Long-Evans rats (Charles River, Raleigh, NC) ranging from 100-200 
days old were used in these experiments.  Pairs of rats were housed in plastic cages in 
a climate-controlled vivarium (lights on 7 A.M. to 7 P.M.), and given ad libitum access to 
food and water.  Testing occurred during the light portion of the cycle.  Rats were 
handled two to three times over one week before surgery and before testing to minimize 
the effects of stress from human contact.  All procedures were approved by the 
Institutional Animal Care and Use Committee of Wayne State University. 
Stereotaxic Surgery 
All surgeries were performed under aseptic conditions. Rats were anesthetized with 
sodium pentobarbital (50 mg/kg, i.p.) following pretreatment with atropine sulfate (1 
mg/kg, i.p.). For implants aimed at CeA, ventral to CeA, and dorsal to CeA, two 
stainless steel 26-gauge single-cannulae (Plastics One, Roanoke, VA) were 
stereotaxically, bilaterally implanted above CeA according to coordinates extrapolated 
from the rat brain atlas of Paxinos and Watson (Paxinos & Watson, 1998). The 
coordinates (in mm) relative to the bregma suture and the top of the flat skull are as 
follows: right implant (AP = -2.0, L = +4.0, DV= -6.0), left implant (AP = -2.0, L = +4.4, 
DV= -6.0). For implants aimed lateral to CeA, two single 26-gauge cannulae were 
bilaterally implanted above positions lateral to CeA using the following stereotaxic 
coordinates (in mm): right implant (AP = -2.0, L = +5.2, DV = -6.0), left implant (AP =  
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-2.0, L = +5.6, DV = -6.0). For implants aimed medial to CeA, two single 26-gauge 
cannulae were bilaterally implanted above positions medial to CeA using the following 
stereotaxic coordinates (in mm): right implant (AP = -2.0, L = +2.8, DV = -6.0), left 
implant (AP = -2.0, L = +3.2, DV = -6.0). 
 For implants aimed toward the vlPAG, one stainless steel 26-gauge single-
cannula (Plastics One, Roanoke, VA) was implanted unilaterally above the vlPAG at a 
twenty-degree angle according to coordinates extrapolated from the rat brain atlas of 
Paxinos and Watson (Paxinos & Watson, 1998). Rats received vlPAG implants on 
either the left or right side based upon random assignment.  The coordinates (in mm) 
relative to the bregma suture and the top of the flat skull were as follows: AP = -7.8, L = 
+2.6, DV= -3.6. 
All cannulae were affixed to the skull with four stainless steel bone screws (3/16 in) 
and cranioplastic cement. Each guide cannula was fitted with a 33-gauge dummy 
cannula that extends the length of the guide to maintain its patency. Rats were given 7-
10 days to recover before the initiation of testing. 
Drug Injections 
Intracerebral CeA injections were administered in a constant volume 0.25μl via 33-
guage injectors. Injectors targeted at CeA extended 3mm beyond the end of the 
cannula. Injectors targeted at sites dorsal to CeA extended 1.8mm beyond the end of 
the cannula, and injectors targeted at sites ventral to CeA extended 4.2mm beyond the 
end of the cannula.  Intracerebral vlPAG injections were administered in a constant 
volume 0.5μl via a 33-guage injector. Injectors targeted at vlPAG extended 3mm 
beyond the end of the cannula.  All injections were made at a constant rate over 1 min 
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via an infusion pump (Harvard Model PHD 2000) and injectors were left in place for 2 
min after the completion of injections to aid the diffusion of drugs into tissue. N-methyl-
D-aspartate (NMDA; Tocris, Ellisville, MO), D-(-)-2-Amino-5-phosphopentanoic acid 
(APV; Tocris, Ellisville, MO), and H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP; 
Sigma-Aldrich, St. Louis, MO) were dissolved in normal sterile saline. 
Histological Analysis 
All rats with the exception of those that underwent Fos expression analysis were 
sacrificed by carbon dioxide asphyxiation at the completion of their testing sequence.  
Injection sites were marked by safrin-O dye (0.25µl) and brains were extracted and 
placed in a 20% (w/v) sucrose formalin solution for 48-72 hours.  Brains were sectioned 
at 45µm on a freezing microtome, and injection sites were localized with the aid of the 
Paxinos and Watson (1998) brain atlas by a researcher unaware of the results from 
behavioral testing. 
Rats from the NMDA dose response study that received the highest NMDA dose 
(1µg/.25µl per side) were stained using cresyl violet in order to assess the potential 
neurotoxic effects of NMDA qualitatively.  Stained tissue was histologically examined at 
10X magnification and compared to stained tissue from rats that received saline 
injections.  Neuronal cell loss or proliferation of glial cells surrounding the NMDA 
injection site was considered evidence for neurotoxic damage. 
2.2 Experimental Design 
Dose Response Analysis 
 To quantify a dose-response relationship between CeA-administered NMDA agonist 
and SMR, VDS, and VAD thresholds, rats received bilateral injections of one dose of 
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NMDA (0.1μg, 0.25μg, 0.5μg, and 1μg/side) and saline into the CeA prior to two 
separate test sessions.  Injections of drug were given over 2 min, and the injector 
remained in place for 1 min to aid in the diffusion of drug into tissue.  Doses of NMDA 
were determined by preliminary results.  Saline injections were maintained as the first 
test in order to ascertain baseline levels of responding.  Test sessions were separated 
by 4 – 6 days, each drug group contained 6 or 7 rats, and the saline group contained 21 
rats (summation of saline treatments from all rats in all drug treatment groups).   
Anatomical Specificity 
 The anatomical specificity of NMDA mediated antinociception within the CeA was 
evaluated by administration of NMDA (1μg/side) into sites surrounding the CeA.  Rats (n 
= 7) received a saline test followed by a test with NMDA agonist on separate test 
sessions at each of three separate anatomical sites by means of injectors that extend 
1.8mm, 3.0mm, and 4.2mm beyond the length of the guide cannulae (see Figure 3 for a 
schematic of injector placement).  Test sessions were separated by 5 – 7 days.  NMDA 
administration within the CeA in this study permitted the replication of NMDA (1μg/side) 
on response thresholds, and these data were used to compare the effects of NMDA 
administered into sites surrounding the CeA. 
CeA NMDA – vlPAG CTAP Interaction 
 Rats (n = 8) first received three testing sessions (sessions separated by 5 – 7 days) 
with different pairs of injections separated by 15 min in the following order: CeA saline + 
vlPAG saline; CeA saline + vlPAG CTAP (0.25µg/0.5µl); CeA NMDA (0.025µg/0.25µl 
per side) + vlPAG saline.  These tests allowed for the assessment of baseline 
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responding, CTAP effects on baseline responding, and the replication of NMDA-induced 
antinociception, respectively. 
 The capacity for vlPAG mu-opiate receptors to mediate CeA-NMDA induced 
antinociception was evaluated by a final test using the following pair of injections: CeA 
NMDA + vlPAG CTAP.   
 The dose of NMDA was determined following preliminary experimentation to 
determine the dose of NMDA that consistently produced elevations in threshold that 
were below ceiling.  This permitted the measurable capacity for CTAP to attenuate the 
effects of NMDA.  The dose of CTAP used was determined following preliminary 
experiments.   
2.3 Pain Testing 
Testing Apparatus 
Rats were placed into custom made Velcro body suits and restrained on a Plexiglas 
pedestal using Velcro strapping that passes through loops located on the underside of 
the suits.  This design maintained the rat in a crouched posture throughout testing and 
permitted unobstructed access to the head for intracerebral injections.  Testing was 
conducted within a sound attenuating, lighted, and ventilated chamber equipped with a 
small window that enabled visual monitoring of the animal during testing. 
Tail-shock  (20ms pulses at 25Hz for 1,000ms) was delivered by a computer 
controlled constant current shocker (STIMTEK, Arlington, MA) through electrodes  
(0-gauge stainless steel insect pins) placed intracutaneously on opposite sides of the 
tail, 7.0cm (cathode) and 8.5cm (anode) from the base.  The utility of this form of tail-
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shock as a noxious stimulus has been extensively discussed (Borszcz, 1993, 1995b; 
Borszcz, et al., 1994; Bromm & Meier, 1984).   
Spinal motor reflexes (SMRs) were measured with a semi-isotonic displacement 
transducer (Lafayette Instruments Model 76614, Lafayette, IN) attached to the rat’s tail 
with cotton thread.  The output voltage of the transducer was amplified (x50) and then 
digitized (500Hz sampling rate) by an analog-to-digital converter of the microcomputer.  
SMR was defined as movement of the transducer arm by at least 1mm following shock 
onset.    
Vocalizations were recorded by a pressure-zone microphone (Realistic model  
33-1090, Tandy, Ft. Worth, TX) located on the wall of the testing chamber 15cm from 
the rat’s head.  The microphone was connected to an audio amplifier (Technics model 
SA-160, Tandy, Ft. Worth, TX) and a 10-band frequency equalizer adjusted to 
selectively amplify frequencies above 1500Hz.  The filtering of low frequencies 
prevented extraneous noise (i.e., rats’ respiration and movement artifacts) from 
contaminating vocalization records.  The output of the amplifier was integrated by a 
Coulbourn Instruments (Allentown, PA) contour following integrator (2ms time base) and 
digitized (500Hz sampling rate) by a separate analog-to-digital converter of the 
microcomputer.   
Performance Measurement  
Performance variables for each animal were recorded by the microcomputer during 
every test.  SMR performance consists of the latency (ms), peak amplitude (mm), and 
magnitude (cm x ms) of tail movement on each trial.  Vocalization performance includes 
the peak intensity (in decibels: SPL, B scale), latency (ms), and duration (ms) of 
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vocalizations during the shock epoch (VDS = vocalization during shock) and for the 
2,000 ms interval following shock termination (VAD = vocalization afterdischarges).  
Previous studies revealed that changes in these performance variables reflect the 
confounding influence of motor impairments on increases in response thresholds 
(Borszcz, 1993; Borszcz, et al., 1994). 
Testing Protocol 
For two consecutive days prior to testing, rats were be adapted to the testing 
apparatus for a period of 20 min each day to minimize the effects of restraint.  For all 
studies, testing began 6-10 min following completion of intra-CeA injections.  Test 
sessions consisted of 20 randomly presented trials.  On 16 trials, tail-shocks between 
0.02 mA and 2.50 mA were delivered, and on four trials no current was delivered so as 
to assess false alarm rates.  Trials were presented with a minimum intertrial interval of 
30 sec and each test session concluded within 20 min.  These procedures cause no 
observable damage to the tail.  Following each test session, the testing apparatus was 
cleaned with 5% ammonia hydroxide to eliminate stress odors (Fanselow, 1985).  
Data Analysis 
Threshold data was reorganized in ascending order according to tail-shock intensity.  
SMR, VDS, and VAD thresholds for each rat were calculated as the minimum current 
intensity from a string of at least two consecutive intensities that generated the 
response.  All analyses used alpha = .05.   
Response thresholds for the NMDA dose response experiment were directly 
compared using repeated-measures MANOVA.  A significant omnibus MANOVA was 
followed by within-subjects contrasts of response thresholds.  The effects of dose on 
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individual responses were analyzed by one-way ANOVA.  The doses of NMDA that 
elevated response thresholds above baseline levels (i.e., saline thresholds) were 
determined by comparing thresholds following saline and NMDA treatments using 
Dunnett’s test.  The capacity of NMDA to elevate response thresholds following its 
injection into sites surrounding the CeA was analyzed for each response by one-way 
ANOVA.  Post-hoc comparisons using independent samples t-tests were used to 
assess response thresholds generated following the administration of NMDA (1µg/.25µl 
per side) or saline into the CeA and into sites surrounding the CeA.  The capacity of 
vlPAG-CTAP to reduce NMDA-CeA induced elevations of response thresholds was 
analyzed across treatment groups for each response by a one-way ANOVA followed by 
post-hoc independent samples t-test.   
Testing sessions that included a threshold greater than 2.0 standard deviations from 
the mean threshold was considered an extreme outlier and was excluded from analysis 
(n = 2).  Rats with incorrectly placed cannulae were also excluded from analysis (n = 2).  
Rats were also excluded from analysis due to death during surgery (n = 1), illness  
(n = 2) or complications related to their surgical cannulae implants (n = 3).    
2.4 Immunohistochemistry 
Experimental Design - CONTEXT 
 Male Long Evans rats were first randomly assigned to one of three context groups: 
Home Cage, Chamber Only, and Shock.  Home Cage rats resided in the laboratory 
holding room for three consecutive days (at least 3h/day). Chamber Only rats were 
exposed to the afore-described tail-shock vocalization response test chamber, but did 
not receive shock, for three consecutive days (20 min/day) in addition to residing in the 
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laboratory holding room.  Shock rats followed protocol identical to the Chamber Only 
group except that on Day 3 a tail-shock vocalization-response test (see above) was 
given to the rat in the chamber. 
 Rats within each Context group were further randomly assigned to one of three drug 
treatment groups: saline, APV, or NMDA.  Rats were given intra-CeA treatments 
bilaterally.  The doses used in these groups were as follows: saline (0.25µl/side), APV 
(4µg in 0.25µl/side), and NMDA (1µg in 0.25µl/side). 
Free-Floating Immunohistochemistry Protocol 
Two hours after the intracerebral injection, the animals were deeply anaesthetized 
with an overdose of sodium pentobarbital into the liver (120 mg/kg) and transcardially 
perfused with 0.1M phosphate-buffered saline (pH = 7.4) followed by 4% 
paraformaldehyde (PFA) in 0.1M PBS (pH 7.4; 4° C). The brains were removed and 
post-fixed at 4° C for 1.5 hours in 4% PFA and then stored for at least 48 hours in 30% 
sucrose in 0.1M PBS at 4° C for cryoprotection or in long-term cryoprotectant (0.1M 
PBS + ethylene glycol + sucrose) at -20° C.  Brains were sliced transversely at 45µm 
and vlPAG sections with the AP coordinates -7.64 through -8.72 mm posterior to 
Bregma were collected. 
Tissue sections were collected in 0.1M PBS and subsequently processed free-
floating according to the avidin–biotin-peroxidase complex (ABC) method. Primary 
antibody concentrations were determined (1:5000) following a titration protocol that 
varied the concentration of primary while leaving the secondary at a constant (1:200 per 
manufacturer).  All reactions were carried out under agitation at room temperature.   
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On the first day, the sections were washed six times (10 min each) in 0.1M PBS and 
then incubated with 0.3% H2O2 for 30 min.  Sections were then washed three times with 
0.1M PBS (5 min each) and then incubated with blocking buffer (0.3% Triton X-100, 1% 
normal goat serum, 1% bovine serum albumin in 0.01M PBS, pH = 7.4) for 60 min to 
reduce non-specific antibody staining.  Sections were then incubated overnight with the 
primary Fos rabbit polyclonal IgG (Santa Cruz, USA) at a concentration of 1:5000 in 
blocking buffer.   
On the second day, sections were washed three times (10 min each) with PBST 
(0.1M PBS with 0.02% Triton X-100) and then incubated for 2 hr with secondary 
biotinylated goat anti-rabbit IgG (H+L) (Vector Laboratories) at a concentration of 1:200 
in blocking buffer.  The sections were then incubated for 1 hr with the avidin and biotin 
complex (A and B solution of the ABC kit, Vector Laboratories) at a concentration of 
1:500 in PBST, and then again washed three times in PBST (5 min per wash) followed 
by two washes in 0.05M Tris-HCl (pH = 7.6; 5 min each).  Finally, chromagen was 
visualized with 0.005% 3,3’V-diaminobenzidine (Sigma), 0.6% nickel ammonium sulfate, 
and 0.005% H2O2 in 0.05M Tris-HCl.  Tissue sections were washed twice with 0.05 M 
Tris-HCl (5 min each) and then washed in distilled water for 10 min. 
Quantification of Fos-Positive Cells 
Tissue sections were mounted on gelatin-coated slides, dehydrated, coverslipped, 
and photographed at with a Nikon Eclipse 80i microscope with a digital camera attached 
to it (Cool Snap Photometrics EZ). The vlPAG was photographed at 40x and compared 
to the rat brain atlas (Paxinos & Watson, 1998) as an orientation aid for tracing the 
vlPAG.  Images were magnified to 200x, and a 400µm x 300µm box was placed within 
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the confines of the vlPAG.  Fos immunoreactivity was visualized as a dark reaction 
product inside neuronal nuclei.  The number of Fos-positive nuclei was counted in the 
box by hand with the aid of a computerized cell counting system (Nikon Elements 
Software, 3.1).  The vlPAG was bilaterally counted in each rat and counted on three to 
four separate sections collected from each rat.  The results are expressed as the 
number of Fos-positive nuclei. 
Data Analysis 
The number of Fos-positive nuclei is expressed as mean ± S.E.M.  Results were 
analyzed using a two-way between-subjects ANOVA with drug treatment (saline, APV, 
NMDA) and context (Home Cage, Chamber, Shock Test) as between-group factors 
followed by one-way ANOVAs with Dunnett’s post-hoc tests.  The alpha level was .05 
for all analyses.   
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CHAPTER 3 
RESULTS 
3.1 NMDA Dose Response Analysis 
The effects of the bilateral administration of NMDA into the CeA on SMR, VDS, 
and VAD thresholds are depicted in Figure 2, and the distribution of the bilateral 
administration sites are depicted as black triangles in Figure 4.  The repeated-measures 
MANOVA (Wilk’s λ) comparison of response thresholds revealed significant main 
effects of response (F(2,41) = 122.06, p < 0.001) and dose (F(4,42) = 21.94, p < 0.001), 
and a significant Response x Dose interaction, (F(8,82) = 11.30, p < 0.001).  One-way 
ANOVA revealed that VDS and VAD thresholds were elevated in a dose-dependent 
manner by NMDA administration [VDS: F(4,46) = 9.75, p < 0.001; VAD: F(4,46) = 32.28, 
p < 0.001], but NMDA treatments did not affect SMR thresholds, F(4,46) = 2.44, p > 
0.05.  Post-hoc analysis using Dunnett’s test revealed that 0.25µg NMDA was the 
minimum dose required to significantly elevate VDS thresholds (M = 1.00, SEM = .31) 
above those observed with saline treatment (M = .06, SEM = .01).  Dunnett’s test 
revealed that 0.1µg NMDA was the minimum dose required to significantly raise VAD 
thresholds (M = .66, SEM = .14) above those observed with saline treatment (M = .10, 
SEM = .01).  Dunnett’s test revealed that bilateral 0.1µg NMDA administration 
preferentially elevated the VAD response over the VDS response, (VAD: M = .66, SEM 
= .14; VDS: M = .22, SEM = .05, respectively).    
3.2 NMDA Anatomical Specificity 
Bilateral administration of saline into the CeA and sites surrounding CeA did not 
produce a significant difference in response thresholds, t(17) = 0.20, p > .05; thus, these 
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data were combined.  The effects of bilateral administration of saline and 1µg NMDA 
into the CeA and sites surrounding CeA are depicted in Figure 5.  
 One-way ANOVAs revealed that vocalization thresholds differed with respect to 
treatment location (Fs(2,37) > 24.76, p < .05), but SMRs did not differ (F(2,37) = .88, p > 
.05).  Independent samples t-tests revealed that 1µg NMDA administration into the CeA 
significantly elevated VDS and VAD thresholds above those observed with saline 
administration (ts(28) > 6.29, p < .05).  Independent samples t-tests further revealed 
that 1µg NMDA administration into sites surrounding the CeA produced significantly 
weaker elevations on VDS and VAD thresholds compared to the administration of 1µg 
NMDA into the CeA (ts(17) > 3.27, p < .05).  Figure 4 depicts administration sites where 
NMDA effectively elevated (black squares, NMDA-CeA) or failed to elevate (black 
circles, NMDA-other) VAD thresholds. 
3.3 Neurotoxicity Analysis 
 Cresyl violet stained CeA sections from rats that received bilateral microinjections of 
1µg NMDA did not produce any pattern of neuronal cell loss or proliferation of glial cells.  
See Figure 11 for representative sections from an animal treated with bilateral CeA-
saline and bilateral CeA-1µg NMDA.  As depicted, there is no evidence of neurotoxicity 
within the NMDA CeA section compared to the saline treated section. 
3.4 CeA NMDA – vlPAG CTAP Interaction 
 The effects of the bilateral administration of 0.025µg NMDA into the CeA challenged 
by the unilateral administration of 0.25µg CTAP into the vlPAG on SMR, VDS, and VAD 
thresholds are depicted in Figure 6, and the distribution of the administration sites are 
depicted as black circles in Figure 7.   
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 One-way ANOVA revealed a significant interaction between CeA treatment and 
vlPAG treatment for SMR and VAD thresholds (Fs(1,32) > 6.00, ps < .05), but not VDS 
threshold (F(1,32) = 2.64, p < .05).  Two points can explain the SMR interaction.  First, 
the variability of the NMDA-CeA + CTAP-vlPAG group is extremely small.  Second, 
mean data suggests that sal-CeA + CTAP-vlPAG treatment tends to elevate SMR 
threshold, but NMDA-CeA + CTAP-vlPAG treatment tends to lower SMR threshold.  
Independent samples t-test (one-tail) revealed that, as expected given the dose-
response analysis, NMDA-CeA + sal-vlPAG treatment resulted in a significant elevation 
of VAD threshold above that observed with sal-CeA + sal-vlPAG treatment (t(14) = 2.29, 
p < .05).  Independent samples t-test (one-tail) revealed that, as hypothesized, NMDA-
CeA + CTAP-vlPAG treatment significantly attenuated VAD threshold compared to 
NMDA-CeA + sal-vlPAG treatment (t(14) = 1.87, p < .05). 
3.5 Fos Expression within vlPAG  
 The effects of bilateral intra-CeA treatment and context on the number of Fos-
positive nuclei within the vlPAG are depicted in Figure 8.  Representative sections with 
Fos expression are shown in Figure 9.  The two-way ANOVA (treatment x context) 
revealed a significant main effect of treatment on the number of Fos-positive nuclei 
within the vlPAG (F(2,36) = 59.86, p < .05) and a significant treatment x context 
interaction (F(4,36) = 3.53, p < .05), but did not reveal a main effect of context (F(2,36) 
= .03, p > .05).  One-way ANOVA revealed significant simple effects within the Home 
Cage, Chamber Only, and Shock contexts (Fs(2,11) > 4.46, ps < .05).  Post-hoc 
analysis via Dunnett’s revealed that within the Home Cage context, the number of intra-
vlPAG Fos-positive nuclei was greater in animals that received bilateral intra-CeA 1μg 
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NMDA (M = 29.22 ± SEM = 4.23) compared to animals that received intra-CeA saline 
(M = 5.58 ± SEM = 0.89) and intra-CeA 4μg APV (M = 7.78 ± SEM = 0.85).  Within the 
Chamber Only context, the number of intra-vlPAG Fos-positive nuclei was greater in 
animals that received bilateral intra-CeA 1μg NMDA (M = 21.07 ± SEM = 3.63) 
compared to animals that received intra-CeA 4μg APV (M = 8.73 ± SEM = 0.82).  Within 
the Shock Test context, the number of intra-vlPAG Fos-positive nuclei was greater in 
animals that received bilateral intra-CeA 1μg NMDA (M = 32.05 ± SEM = 3.32) 
compared to animals that received intra-CeA saline (M = 4.35 ± SEM = 0.90) and intra-
CeA 4μg APV (M = 5.67 ± SEM = 1.29).   
 One-way ANOVA revealed that SMR, VDS, and VAD thresholds in the Shock 
Test Context differed with respect to CeA treatment (Fs(2,61) > 5.24, ps < .05).  
Independent samples t-tests revealed that compared to saline, SMR, VDS and VAD 
thresholds were elevated to a greater extent following 4µg APV (ts(45) > 2.73, ps < .05) 
and 1µg NMDA (ts(48) > 3.01, ps < .05).  SMR and VAD threshold were not significantly 
different between 4µg APV and 1µg NMDA (ts25) < 1.83, ps > .05), but VDS threshold 
was significant (t(25) = 2.28, p <.05).   
 Figure 10 depicts mean threshold data for saline, APV, and NMDA from animals 
in the Fos, APV dose response, NMDA dose response, and CeA-vlPAG Interaction 
studies.  Independent samples t-tests (one-tailed) revealed that compared to intra-CeA 
saline treatment, bilateral intra-CeA APV (t(45) = 7.86, p < .05) and NMDA (t(48) = 
14.08, p < .05) significantly elevated VAD thresholds.  Threshold elevations following 
APV treatment did not significantly differ from those following NMDA treatment (t(25) = 
1.83, p < .05). 
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3.6 Performance Analysis 
3.6.1 Response Profiles 
Of the four experiments that composed this study, 388 test trials were sham trials 
(i.e., no shock given).  False alarm rates were low (SMR = 1.80%, VDS = 0.00%, VAD = 
0.00%) and indicate that behaviors did not occur spontaneously or as a result of drug 
treatment, but instead were generated via tail-shock.  SMR, VDS, and VAD reflect 
nociceptive processing at progressively higher levels of the neuraxis. Analysis of rats 
that received transections of the neuraxis revealed that SMR responses are organized 
at the spinal level, VDS within the medulla below the pontomedullary border, and VAD 
within the forebrain (Borszcz, Johnson, Anderson, & Young, 1992; Carroll & Lim, 1960). 
On the remaining 1,552 trials where tail-shocks were administered, responses 
organized rostrally within the CNS were rarely generated without those integrated more 
caudally within the CNS. VAD generation, without concomitant elicitation of VDS and 
SMR, occurred on 0.58% of all trials. VDSs were elicited without SMR on 0.32% of the 
trials in which VDS was the most rostrally elicited response.   
3.6.2 Response Characteristics 
SMR reaction time (SMR.RT), amplitude (SMR.AMP), and magnitude 
(SMR.MAG); VDS reaction time (VDS.RT), amplitude (VDS.AMP), and duration 
(VDS.DUR); and VAD reaction time (VAD.RT), amplitude (VAD.AMP) and duration 
(VAD.DUR) were recorded at threshold for vehicle and each drug treatment condition 
(see Table 1, mean ± standard error of the mean), and compared to saline treatment 
threshold (i.e., baseline) using a one-way ANOVA with Dunnett’s post-hoc tests (see 
Table 2).    
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NMDA Dose Response and Anatomical Control Studies 
Comparison of SMR performance variables across saline and NMDA drug 
treatments revealed that SMR performance at threshold was not affected by NMDA 
treatments, Fs(4,83) < 0.81, ps > .05.  Comparison of VAD performance variables 
across saline and NMDA drug treatments revealed that VAD performance at threshold 
was not affected by NMDA treatments, Fs(4,74) < 2.26, ps > .05.  Comparisons of VDS 
performance variables demonstrated that reaction time of VDSs at threshold were not 
altered by NMDA treatment (F(4,79) = 1.21, p > .05), but the amplitude and duration of 
VDSs were significantly lower following NMDA treatments, Fs(4,79) > 3.18, ps < .05.  
Post-hoc analysis revealed that the amplitude of VDS was decreased compared to 
baseline following bilateral administration of 1µg NMDA.   Post-hoc analysis revealed 
that the duration of VDS was decreased compared to baseline following bilateral 
administration of 0.25µg NMDA, 0.5µg NMDA and 1µg NMDA.  The effect on VDS 
amplitude is small (M1µg NMDA = 85.52 ± SEM = 1.22 vs. Msaline = 90.06 ± SEM = 0.94) 
and did not occur in other experiments.  The effects on VDS duration also did not occur 
in the 1µg NMDA group in the Fos Expression Study – Shock Group.   
CeA – vlPAG Interaction Study 
Comparison of SMR, VDS, and VAD performance variables across baseline 
(saline CeA + saline vlPAG) and drug treatments revealed that all response 
characteristics were not significantly affected by treatment, Fs(3,30) < 1.40, ps > .05.   
Fos Expression Study – Shock Group 
Comparison of performance variables across bilateral intra-CeA saline, 4µg APV, 
and 1µg NMDA revealed that all response characteristics were not significantly affected 
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by treatment (SMR: Fs(2,11) < 1.54, ps > .05; VDS: Fs(2,8) < 2.38, ps > .05; VAD: 
Fs(1,6) < 2.32, ps > .05).  Three animals in the 1µg NMDA group did not respond to any 
shock intensity with a VDS, and thus only one animal’s threshold data is reported for 
VDS.RT, VDS.AMP, and VDS.DUR.  Likewise, all four animals in the 1µg NMDA group 
did not respond to any shock intensity with a VAD, and thus no threshold data could be 
reported for VAD.RT, VAD.AMP, and VAD.DUR. 
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CHAPTER 4 
DISCUSSION 
The present study provides the first demonstration of behavioral antinociception 
generated by administration of an NMDA receptor agonist into the CeA.  Administration 
of NMDA into the CeA produced dose-dependent increases in VAD and VDS thresholds 
but failed to elevate SMR threshold.  Direct comparisons of response thresholds 
revealed that VAD threshold was preferentially elevated compared to VDS threshold by 
the intra-CeA injection of NMDA, and the minimum effective dose of NMDA to elevate 
VAD threshold was lower than the dose that raised VDS threshold.  The increases in 
VAD threshold cannot be attributed to drug-induced motor deficits as increases in VAD 
threshold were not accompanied by performance decrements.  Increases in VDS 
threshold may reflect the effects of drugs on performance.  NMDA produced decreases 
in VDS duration at threshold and increases in VDS latency at threshold.  Decrements in 
these performance variables following systemic drug treatments (i.e., morphine, 
diazepam) were shown to elevate response thresholds independent of the drugs’ effect 
on sensory processing (Borszcz, et al., 1994).   However, these decrements were 
relatively small and were not observed in the CeA-NMDA + vlPAG-CTAP interaction 
study. 
Similar to the present results, administration of carbachol, serotonin (5-HT), the 
5-HT1A/7 agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT), or morphine into either 
the basolateral amygdala (BLA), thalamic parafascicular nucleus (nPF), or ventral 
tegmental area (VTA) produced selective increases in VAD and VDS thresholds without 
an accompanying increase in SMR threshold (Harte, Hoot, & Borszcz, 2004; Harte, 
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Kender, & Borszcz, 2005; Harte, Lagman, & Borszcz, 2000; Kender, Harte, Munn, & 
Borszcz, 2008; Nandigama & Borszcz, 2003).  The failure to observe increases in SMR 
threshold does not reflect the resistance of this response to antinociceptive treatments. 
In previous studies, administration of morphine into the rostral ventromedial medulla 
(RVM) or vlPAG produced significant increases in SMR, VDS, and VAD thresholds 
(Borszcz, 1995a; Borszcz, Johnson, & Thorp, 1996; Borszcz & Streltsov, 2000), and the 
intrathecal administration of morphine, 5-HT, or norepinephrine was equally effective in 
raising SMR, VDS, and VAD thresholds (Borszcz, Johnson, & Williams, 1996).  The 
capacity of these central treatments to elevate SMR threshold also demonstrates that 
SMRs are not generated by direct stimulation of the tail musculature by the tail-shock. 
These findings indicate that the capacity to elevate SMR threshold depends on the site 
within the CNS at which antinociceptive treatments are administered. 
The capacity of CeA-administered NMDA to elevate vocalization thresholds is 
likely limited to its action within CeA.  Bilateral administration of the highest dose of 
NMDA (1µg/side) into sites surrounding the CeA produced greatly attenuated increases 
in VAD and VDS thresholds.  Thus, it is unlikely that the effects of NMDA observed in 
the dose response study are the result of drug spread into these surrounding sites.  
Further, the effect of NMDA on vocalization thresholds cannot be the result of an 
excitotoxic lesion.  NMDA is a known neurotoxin at high doses, but the doses used in 
the present study are well below those shown to produce cell loss (8 µg; Maisonnette, 
Kawasaki, Coimbra, & Brandao, 1996).  Further, qualitative analysis of cresyl-violet 
stained tissue revealed that bilateral treatment with 1µg NMDA failed to produce cell 
loss.  Additional evidence against elevations of vocalization thresholds being the result 
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of a lesion comes from the results of the CeA-NMDA + vlPAG-CTAP study, as CeA-
NMDA induced vocalization threshold elevations were attenuated via vlPAG-CTAP 
administration.  If the threshold elevations were due to a lesion of CeA, CTAP would be 
unable to reverse these elevations.  This result also argues against the observed effects 
on vocalization thresholds being the consequence of NMDA induced elliptic-type neural 
activity producing a functional lesion in CeA (Frenk & Yitzhaky, 1981).  Therefore, the 
capacity of NMDA administered into the CeA to suppress pain-induced vocalizations is 
the result of activation of NMDA receptors within CeA. 
The preferential increase in VAD threshold after intra-CeA APV or NMDA 
administration reflects suppression of the affective reaction to noxious stimulation.  
Previous research in this laboratory validated VADs as a rodent model of pain affect.  
VADs have distinct spectrographic characteristics compared to VDSs (Borszcz, 1995b, 
2006; Borszcz & Leaton, 2003), and are preferentially suppressed by systemically 
administered drug treatments that preferentially suppress the affective response of 
humans to pain (Borszcz, et al., 1994; Gracely, et al., 1978; Price, von der Gruen, 
Miller, Rafii, & Price, 1985).  Generation of VADs is also suppressed by damage of or 
drug treatments into forebrain sites known to contribute to production of the affective 
response of humans to clinical and experimental pain (Borszcz, 1999; Borszcz & 
Leaton, 2003; Greer, 2007; Harte, et al., 2005; Harte, et al., 2000; Hoffmeister, 1968; 
Mark, Ervin, & Yakovlev, 1961; Nandigama & Borszcz, 2003; Sweet, 1980; Zubieta, et 
al., 2001).  Additionally, the capacity of noxious tail-shock to support fear conditioning is 
directly related to its production of VADs (Borszcz, 1993, 1995b; Borszcz & Leaton, 
2003), and fear conditioning supported by electrical stimulation of the ventromedial 
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hypothalamus is correlated with generation of VAD-like vocalizations (i.e., vocalizations 
with the same spectrographic characteristics as VADs; (Borszcz, 2006).  
It is of interest that both the NMDA receptor antagonist APV (Spuz & Borszcz, in 
preparation) and the agonist NMDA produce similar behavioral effects when 
administered within the CeA.  NMDA receptors have been identified in the medial (CeM) 
and capsular (CeC) subnuclei of the CeA in rat (Farb, Aoki, & Ledoux, 1995; Gracy & 
Pickel, 1995).  It is proposed that manipulation of NMDA receptors within CeA produces 
affective analgesia, measured as elevations in VAD thresholds, via the action of APV 
and NMDA at separate neural populations within CeC and CeM, respectively.   
4.1 Model of Intra-CeA APV-Induced Affective Analgesia 
The CeA receives nociceptive-specific information from the spinal cord dorsal 
horn via the indirect spino-parabrachio-amygdaloid (Bernard & Besson, 1990; Ma & 
Peschanski, 1988; Todd, et al., 2002) pathway and the direct spino-amygdaloid 
pathway (Burstein & Potrebic, 1993; Cliffer, Burstein, & Giesler, 1991; Newman, et al., 
1996).  Electrophysiology studies indicate that the lateral region of CeC (CeALC) 
contains the greatest proportion of neurons activated by noxious peripheral stimulation 
of the rat body (Bernard, et al., 1992).  Stimulation of these CeALC neurons 
antidromically activates pontine parabrachial (PB) neurons that respond exclusively to 
noxious cutaneous stimulation (Bernard & Besson, 1990).  In-vitro whole-cell voltage-
clamp recordings of rat CeALC neurons revealed that following PB electrical stimulation, 
CeALC neurons exhibit monosynaptic excitatory post-synaptic currents (EPSCs; Bird, et 
al., 2005).  Bath application of APV to the slices does not alter evoked EPSCs, 
suggesting that glutamatergic pain transmission via the PB-CeALC pathway does not 
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interact with CeALC-NMDA receptors.  However, in vivo investigations showed that 
administration of APV into the CeALC of rats does attenuate noxious, but not 
innocuous, evoked neural activity in the CeALC (Li & Neugebauer, 2004a).  Thus, 
NMDA dependent nociceptive neural transmission interacting with the CeALC must 
project from regions other than the PB.  An alternative pathway for NMDA dependent 
glutamate neurotransmission to interact with CeA is via the direct spino-amygdaloid 
pathway.  To the best of our knowledge, no study has investigated whether glutamate is 
the major neurotransmitter involved in this direct spinoamygdaloid projection.  Also as 
described earlier, the CeA receives nociceptive input relayed from the spinal dorsal horn 
via the intralaminar thalamus, yet no study has investigated the neurochemistry 
underlying these thalamic afferents or their contribution to noxious-evoked activity in the 
CeA. 
Our previous demonstration that intra-CeA administration of APV produces dose-
dependent increases in vocalization thresholds, with a preferential influence on VAD 
thresholds (Siegel, 2005; Spuz & Borszcz, in preparation) likely reflects the suppression 
of nociceptive processing at the level of the CeALC NMDA receptors.  This blockade 
inhibits the further transmission of nociception to efferent sites of the CeA that 
coordinate affective responding to noxious stimulation.  As noted earlier, CeA is the 
major output nucleus of the amygdaloid complex, and its projections to the ventromedial 
hypothalamus (VMH) and dorsolateral PAG (dlPAG) govern the execution of innate 
affective reactions to environmental threats, including pain (Borszcz & Spuz, 2009).  
The dorsomedial division of the VMH (dmVMH) and dlPAG are the core mesolimbic 
structures that control execution of affective responses to environmental threats (Siegel, 
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2005).  Both the dmVMH and dlPAG exhibit Fos activation following exposure to either 
noxious or non-noxious threatening stimuli (Beckett, Duxon, Aspley, & Marsden, 1997a; 
Bullitt, 1990; Canteras, Chiavegatto, Ribeiro do Valle, & Swanson, 1997; Dielenberg, 
Hunt, & McGregor, 2001; Liu, Qiang, & Qiao, 1998; Parry, Semenenko, Conley, & 
Lumb, 2002; Rodella, Rezzani, Gioia, Tredici, & Bianchi, 1998; Sandner, et al., 1993), 
and inactivation or damage of these sites block naturally occurring affective responses 
to threats (Canteras, et al., 1997; Cheu & Siegel, 1998; Markham, Blanchard, Canteras, 
Cuyno, & Blanchard, 2004).  Stimulation of the dmVMH and dlPAG elicits affective 
responses in rats, cats and monkeys (Fernandez De Molina & Hunsperger, 1962; Lipp 
& Hunsperger, 1978; Milani & Graeff, 1987), and in humans generates reports of fear, 
anxiety, and horror (Ervin, Mark, & Stevens, 1969; Heath, 1975; Iacono & Nashold, 
1982; Tasker, 1982).  For all these species, vocalizations are part of their affective 
reaction to imminent threat and are produced as part of their affective reaction to 
dmVMH or dlPAG stimulation (Blanchard, Hynd, Minke, Minemoto, & Blanchard, 2001; 
Blanchard, Flannelly, & Blanchard, 1986; Fernandez De Molina & Hunsperger, 1962; 
Jurgens & Pratt, 1979). 
Previous research in this laboratory (Borszcz, 2006) demonstrated that electrical 
or chemical stimulation of dmVMH generates VAD-like vocalizations.  Manipulation of 
GABAA neurochemistry within the dmVMH altered the threshold for elicitation of VADs 
by dmVMH electrical stimulation or tail-shock.  Administration of the GABAA antagonist 
bicuculline or the GABAA agonist muscimol into the dmVMH lowered and elevated VAD 
threshold, respectively. These treatments did not alter thresholds of VDS or SMR 
elicited by tail-shock.  Bicuculline and muscimol administered into the dmVMH also 
 
37 
elevated and lowered the asymptotic level of fear conditioning supported by dmVMH 
stimulation or tail-shock.  
The dlPAG serves as the interface between limbic forebrain sites that process 
stimuli that threaten the individual and execution of innate affective responses that 
enable the individual to cope with the threat (Bernard & Bandler, 1998; Jurgens & Pratt, 
1979; Keay & Bandler, 2001).  Inputs from the dmVMH to the dlPAG activate 
descending dlPAG projections to the brainstem that coordinate the execution of the 
behavioral and autonomic responses that constitute affective responding.  These 
projections are activated by nociceptive input to the dmVMH.  Neurons within dmVMH 
that exhibit Fos expression following presentation of a noxious cutaneous stimulus are 
double-labeled by administration of a retrograde tracer into the dlPAG (Parry, et al., 
2002).  Projections from the dlPAG to the rostral ventrolateral medulla initiate the 
autonomic reactions associated with affective responses to threats (Lovick, 1992; Wang 
& Wessendorf, 2002).  Projections from the dlPAG to the nucleus retroambiguus initiate 
activity in the laryngeal, articulatory, and respiratory motor neurons that generate 
affective vocalizations (Jurgens, 2002).   
As depicted in Figure 13, nociceptive input to the CeA activates the dmVMH  
dlPAG  brainstem circuit for generation of VADs.  Suppression of VADs that follows 
administration of APV into the CeA is posited to reflect inhibition of nociceptive 
throughput to the dmVMH and related interconnected limbic sites.  Consequently, 
nociceptive input is unable to gain access to the mesolimbic circuit responsible for 
generating affective behaviors to threats.  As vocalizations are a common affective 
response to imminent threats and exposure to a noxious stimulus is the prototypical 
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imminent threat, the interruption of pain input to this circuit suppresses the rat’s affective 
vocalizations to pain (i.e., VADs).  As Charles Darwin noted concerning the emission of 
pain-induced vocalizations (Darwin, 1898): 
 “When animals suffer from an agony of pain, they generally writhe about with frightful 
contortions; and those which habitually use their voices utter piercing cries or groans.” 
 
 “Great pain urges all animals, and has urged them during endless generations, to make 
the most violent and diversified efforts to escape from the cause of suffering…. As the 
muscles of the chest and vocal organs are habitually used, these will be particularly 
liable to be acted on, and loud, harsh screams or cries will be uttered.” 
 
4.2 Model of Intra-CeA NMDA-Induced Affective Analgesia 
Alternately, elevations in vocalization thresholds following intra-CeA NMDA 
administration may reflect the action of this drug at NMDA receptors within the medial 
subdivision of the CeA (CeM).  Figure 13 depicts excitatory projections from CeM that 
activate vlPAG inhibitory projections to the CeALC and dmVMH.  NMDA receptor 
activation within CeM is postulated to engage efferent projections of CeM that activate 
endogenous antinociceptive mechanisms within the vlPAG.  The CeM projects directly 
to the vlPAG (Rizvi, Ennis, Behbehani, & Shipley, 1991), a midbrain structure critically 
involved in endogenous antinociception.  The neurochemistry of the CeM – vlPAG 
projection as involved in antinociception has yet to be elucidated, however, evidence 
suggests that substance P may play a role.  Substance-P neurons in CeM project to the 
vlPAG (Gray & Magnuson, 1992), neurokinin (NK) receptors are localized on vlPAG 
enkephalin interneurons (Commons & Valentino, 2002), substance P binding to intra-
vlPAG NK receptors evokes the local release of enkephalin (Drew, Mitchell, & Vaughan, 
2005), and activation of vlPAG neurokinin receptors leads to antinociception (Rosen, 
Zhang, Lund, Lundeberg, & Yu, 2004).   
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Thus, CeM-NMDA receptor activation may activate substance P projections that 
interact with the antinociceptive neural circuitry of the vlPAG to produce elevations in 
vocalization thresholds.  Specifically, the aforementioned substance P induced release 
of enkephalin in vlPAG may be the mechanism whereby NMDA administered into the 
CeA produced elevations of vocalization thresholds in the present study.  The internal 
neurochemistry of the vlPAG that contributes to antinociception is well characterized 
and is depicted in Figure 12 (Reichling, 1991; Reichling, Kwiat, & Basbaum, 1988).  The 
vlPAG contains tonically active GABA interneurons that suppress serotonergic output 
neurons.  Enkephalin release within the vlPAG inhibits the GABA interneurons via 
binding with mu-opiate receptors on the GABA interneurons, thereby disinhibiting 
serotonin projection neurons in vlPAG.  The serotonergic projection neurons activate 
antinociceptive processes at the level of the limbic system, thalamus, and brainstem.  
Congruent with this circuitry, morphine administration into the vlPAG and acting at mu-
opiate receptors presumably located on the GABA interneuron, produces elevations in 
vocalization thresholds that are blocked via administration of a serotonin receptor 
antagonist (methysergide) into the amygdala, medial thalamus, or rostral ventral 
medulla (Borszcz, 1995a, 1999).   
As noted earlier, behavioral antinociception generated by CeA activation is 
blocked by inactivation of the vlPAG via local lidocaine injection or administration of a 
mu-opiate receptor antagonist into vlPAG (Leite-Panissi et al., 2003; Oliveira & Prado, 
2001).  Further, electrophysiology experiments demonstrated that glutamatergic 
stimulation of the CeA alters vlPAG neural activity through intra-vlPAG opiate receptors 
(da Costa Gomez & Behbehani, 1995).  Administration of D,L-homocysteic acid, a 
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glutamate agonist, into the CeA results in an approximate 1:1 ratio of vlPAG neural 
excitation to inhibition.  These vlPAG neural responses were suppressed following the 
microiontophoretic application of the opiate antagonist naloxone to the vlPAG.  The 
excitatory and inhibitory responses recorded from the vlPAG may reflect the recording 
of separate neural populations in line with the internal neurochemistry of the vlPAG.  
Excitatory responses following D,L-homocysteic acid likely reflects excitation of the 
vlPAG enkephalin interneurons and/or the serotonergic projection neurons.  Alternately, 
inhibitory responses likely reflect inhibition of GABA interneurons. 
Results of the present study are consistent with the hypothesis that NMDA 
receptor activation in CeA suppresses pain affect through the release of enkephalin in 
vlPAG, which engages antinociceptive projections from the vlPAG.  Compared to 
following injection of saline into the CeA, the administration of NMDA into the CeA 
produced increased Fos expression in the vlPAG.  This difference in Fos expression 
was observed in all three experimental contexts, and therefore is a reliable effect of 
NMDA receptor activation within the CeA.  Presumably, Fos was expressed by 
enkephalinergic interneurons and serotonergic projection neurons of the vlPAG.  This 
assumption is supported by the finding that elevations in VAD threshold induced via 
bilateral intra-CeA administration of NMDA were reduced following the unilateral intra-
vlPAG administration of the mu-opiate specific antagonist CTAP.   
That the vlPAG is involved in producing elevations in vocalization thresholds 
following intra-CeA NMDA, but not intra-CeA APV, is also supported by the present 
results investigating the expression of Fos-positive nuclei in the vlPAG.  Although rats 
who received intra-CeA NMDA exhibited greater numbers of Fos-positive nuclei in the 
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vlPAG compared to rats administered saline into the CeA, this was not the case with 
rats who received APV into the CeA.  Fos expression in vlPAG following administration 
of APV into the CeA did not differ from that observed following administration of saline 
into the CeA.  Importantly, the doses of APV and NMDA administered into the CeA 
produced significant elevations in vocalization thresholds.  These data suggest that 
administration of NMDA into the CeA activates the vlPAG, and the vlPAG contributes to 
the elevation of vocalization thresholds produced by intra-CeA NMDA.  Conversely, 
administration of APV into the CeA does not activate the vlPAG, and thus the vlPAG is 
likely not involved in the elevation of vocalization thresholds produced by intra-CeA 
APV. 
4.3 Interactions of Sub-populations of NMDA receptors in CeA 
 The results of the present study suggest the NMDA receptors within the CeA are 
segregated both anatomically and functionally with regard to the production of 
behavioral antinociception.  Administration of the NMDA receptor antagonist APV or 
agonist NMDA produced a dose-dependent preferential elevation in the threshold of the 
VAD response, which is a validated measure of pain affect in the rat.  Overall, these 
findings indicate that NMDA receptors within the CeA contribute to the processing of 
pain affect.  Administration of APV into the CeA likely produces its antinociceptive 
effects via the inhibition of nociceptive transmission at the level of the CeALC.  
Conversely, the antinociceptive effects elicited via NMDA into the CeA likely are a result 
of the activation of CeM projection neurons that engage antinociceptive mechanisms 
within the vlPAG.     
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 The present finding that NMDA receptor agonism and antagonism within a 
particular structure can produce similar effects on nociceptive processing is consistent 
with earlier findings of this laboratory.  Previously, we reported that administration of 
NMDA into the rostral anterior cingulate cortex (rACC) and APV into the caudal ACC 
(cACC) both generated dose-dependent increases in vocalization thresholds similar to 
that observed in the present study (Greer, 2007).  Because the rACC and cACC are 
sufficiently separated anatomically, it was possible in that study to separately administer 
drugs into either site using our microinjection technique.  The CeA, however, is a much 
smaller structure and the microinjection technique does not permit the spatial resolution 
required to inject APV or NMDA within the boundaries of CeALC or CeM, respectively.  
Thus, administration of either drug likely activates both subpopulations of NMDA 
receptors.   
 It is possible to explain the similar behavioral effects of APV and NMDA using a 
model that describes the neurochemical and anatomical connections of CeALC and 
CeM with structures responsible for the generation of VADs (see Figure 13).  
Administration of NMDA into the CeA activates NMDA receptors within the CeALC.  It 
would be expected that this effect would elicit vocalizations from the rat, given that 
activation of the CeALC would engage the neural circuitry (dmVMH and dlPAG) 
involved in the generation of VADs (Figure 13, CeALC  dmVMH  dlPAG).   
That VADs are not elicited, but rather suppressed, by intra-CeA administration of 
NMDA is posited to be the result of concomitant NMDA receptor activation of the CeM.  
NMDA receptor activation of CeM is proposed to engage, via mu-opiate mediated 
disinhibition, antinociceptive projection neurons from vlPAG that suppress nociceptive 
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processing within the circuit that contributes to production of VADs (Figure 13, CeM  
vlPAG  CeALC and dmVMH).  Activation of serotonergic neurons of the vlPAG that 
project to the CeALC and dmVMH are hypothesized to suppress production of VADs.  
Immunohistochemical retrograde transport double labeling studies revealed that 
serotonergic neurons in vlPAG project to CeA and VMH (Li, Jia, Rao, & Shi, 1990; Li, 
Zeng, Dong, Rao, & Shi, 1991; Smith & Flynn, 1980).  Mu-opiate mediated activation of 
serotonergic projections to CeA contributes to suppression of VADs.  Administration of 
the serotonin receptor antagonist methysergide into the CeA reverses the increase in 
VAD threshold generated by injection of the mu-opiate receptor agonist morphine into 
vlPAG (Borszcz, 1999).  This result is consistent with findings that stimulation of vlPAG 
or systemic administration of morphine increases the efflux and metabolism of serotonin 
in CeA (Spampinato, Esposito, Romandini, & Samanin, 1985; Viana, Graeff, & 
Loschmann, 1997).  The contribution of serotonergic projections from vlPAG to dmVMH 
to the suppression of pain affect has not been evaluated; however, injection of the 5-
HT1A receptor agonist 8-OH-DPAT into the VMH suppressed defensive vocalizations in 
the cat (Hassanain, Bhatt, & Siegel, 2003).   
Findings of electrophysiological studies of the amygdala provide additional 
support for the hypothesis that serotonergic projections from vlPAG to CeALC inhibit 
NMDA receptor mediated nociceptive processing within CeALC.  Although no study to 
date has investigated the ability of serotonin agonists to suppress NMDA-evoked neural 
activity within CeA, several studies suggest such a mechanism.  For example, 
microiontophoretic administration of serotonin onto neurons within the lateral amygdala 
decreased the number of action potentials elicited via microiontophoretic administration 
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of glutamate (Stutzmann & LeDoux, 1999; Stutzmann, McEwen, & LeDoux, 1998).  It is 
likely that serotonin acts directly within the CeA to inhibit NMDA-induced excitation.  
First, 5-HT1A is the primary receptor subtype that mediates post-synaptic serotonin 
induced inhibition (see Saxena, 1995).  Second, 5-HT1A is the predominate serotonin 
receptor found in the CeA (Radja, et al., 1991).  In accordance, iontophoretic application 
of the 5-HT1A receptor agonist 8-OH-DPAT produced a preferential inhibition of 
spontaneous neural activity within the CeA (Stein, Davidowa, & Albrecht, 2000). 
Although the effect of serotonin on noxious-evoked unit activity in the amygdala 
has not been evaluated, serotonin modulates noxious-evoked activity in the 
parafascicular thalamic nucleus (nPF) that is also innervated by serotonergic projections 
of the vlPAG (Chen, Zeng, Rao, & Shi, 1992), and contains 5-HT1A and 5-HT7 receptors 
(Neumaier, Sexton, Yracheta, Diaz, & Brownfield, 2001; Pazos & Palacios, 1985). 
Iontophoretic application of serotonin in the nPF and administration of morphine into the 
vlPAG inhibits noxious evoked neural activity in the nPF.  These effects were blocked 
by local iontophoretic application of the broad-spectrum 5-HT antagonist methysergide 
(Dafny, Reyes-Vazquez, & Qiao, 1990; Reyes-Vazquez, Qiao, & Dafny, 1989). 
Behavioral antinociception produced by vlPAG-administered morphine was also shown 
to be mediated by the activation of serotonin projections to the nPF (Borszcz, 1999; 
Borszcz & Streltsov, 2000).  Increases in VAD and VDS thresholds generated by the 
injection of morphine into vlPAG were reversed in a dose-dependent manner by the 
injection of methysergide into nPF.  Furthermore, systemic administration of morphine in 
a dose that selectively elevates vocalization thresholds increased the release and 
metabolism of serotonin in the nPF (Munn & Borszcz, 2002).  Direct administration of 8-
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OH-DPAT into the nPF selectively elevated VAD and VDS thresholds, which were 
blocked by concurrent administration of the 5-HT1A antagonist WAY 100,635 (Harte, et 
al., 2005).  These findings support the contention that serotonin acting in the CeALC 
may also generate antinociception through inhibition of noxious-evoked activity. 
Previous findings from this laboratory demonstrated that increasing mu-opiate 
receptor activation in the vlPAG (via injection of increasing doses of morphine) 
generates progressive recruitment of serotonergic antinociceptive projections of the 
vlPAG that inhibit nociceptive processing at forebrain, medullary and spinal levels of the 
neuraxis (Borszcz, 1995a, 1999; Borszcz, Johnson, & Thorp, 1996; Borszcz & Streltsov, 
2000).  In the current study, administration of low doses of NMDA into the CeA 
presumably only engage antinociceptive projections of vlPAG that inhibit nociceptive 
processing at forebrain sites responsible for generating VADs (Borszcz, 2006; Borszcz 
& Leaton, 2003; Carroll & Lim, 1960; Hoffmeister, 1968).  As the dose of NMDA 
administered into the CeA was increased, VDS threshold was also elevated.  VDSs are 
organized within the medulla below the pontomedullary border (Carroll & Lim, 1960; 
Hoffmeister, 1968).  The effect of NMDA on VDS threshold is likely due to the 
recruitment of descending serotonergic projections from the CeA that inhibit nociceptive 
processing by medullary neurons responsible for the generation of the VDS response.  
Following administration of a dose of morphine into vlPAG that selectively elevated VAD 
and VDS thresholds, the subsequent injection of methysergide into the RVM restored 
VDS threshold to baseline levels (Borszcz, 1999).   
It is well established that mu-opiate receptor activation of vlPAG inhibits 
nociceptive processing within the spinal dorsal horn via engaging descending spinopetal 
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projections (Basbaum & Fields, 1984; Jensen, 1986; Yaksh & Malmberg, 1994), and 
thereby inhibit withdrawal reflexes (tail-flick, paw withdrawal) elicited by noxious stimuli 
(Carstens, Hartung, Stelzer, & Zimmermann, 1990; Jensen & Yaksh, 1986; Levy & 
Proudfit, 1979; Ossipov, Goldstein, & Malseed, 1984; Yaksh, Yeung, & Rudy, 1976).  
Previous studies in this laboratory revealed that vlPAG administration of morphine at 
high doses is capable of elevating SMR threshold along with VAD and VDS thresholds.  
This increase in SMR threshold is mediated via recruitment of spinopetal projections 
from the rostral ventomedial medulla (Borszcz, 1999).  It is conceivable that 
administration of a dose of NMDA into the CeA larger than that used in the present 
study may indeed elevate SMR threshold.  However, there are limitations to the dose of 
NMDA that can be administered into the CeA without producing a neurotoxic lesion of 
CeA (Maisonnette, et al., 1996). 
4.4 Ethological Relevance 
 The studies presented here provide support for the involvement of NMDA 
receptors within subdivisions of the CeA in the generation of affective analgesia.  The 
perceptual-defensive-recuperative (PDR) theory of fear and pain (Bolles & Fanselow, 
1980) provides insight into the ethological relevance of the present findings.  PDR 
theory contends that fear will inhibit pain because pain-related behaviors will interfere 
with defensive behaviors that occur in response to an imminent predator.  For example, 
an animal engaged in a physical encounter with a predator and that has sustained an 
injury must prevent the emergence of pain-related behavior in order to maintain 
execution of defensive behaviors.  If the animal were to tend to the injury, the animal 
would be rendered defenseless and would provide the predator with an advantage.  
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Suppression of pain signaling would allow the animal to devote attention to the predator 
rather than to the pain.  
 Ethological evaluation of the behavior of rodents, other mammals, and humans 
revealed that individuals produce a series of defensive behaviors when confronted with 
a threat (Blanchard & Blanchard, 1969, 1987; Blanchard, et al., 1986; Fanselow & 
Lester, 1988).  Proximity of the individual to the threat (i.e., predatory imminence) and 
various environmental constraints (availability of escape routes) governs expression of 
particular behavior patterns within the series of defensive reactions.  For the rat, the 
presence of a distant predator results in the cessation of movement (freezing) in order 
to make the individual less conspicuous.  As a predator approaches and escape routes 
are available then rats engage in escape behaviors.  When contact with the predator is 
imminent and an escape route is not available, rodents engage in defensive aggression 
as exemplified by threat-attack behaviors.  The rat rears-up to face the predator, 
displays its teeth, and emits sonic vocalizations (see Figure 14).  Continued approach 
by the predator elicits jump-attacks of the rat upon the predator.  Resultant physical 
contact with the predator involves continued sonic vocalizations, struggling, biting, and 
escape attempts.  Defensive aggression serves to thwart the attack of a predator, or to 
escape the predator’s grasp or the source of noxious stimulation.  Post-encounter 
defensive reactions include ultrasonic vocalizations, hyperalgesia, and finally 
recuperative behaviors.   
Evaluation of defensive responding by humans revealed a similar pattern of 
defensive behaviors.  The proximity of the subject to the source of threat and the 
availability of escape routes determined whether humans engaged in freezing, flight, or 
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defensive aggression (Blanchard, et al., 2001).  Human imaging studies that utilized a 
virtual maze and virtual predators revealed activation of brain areas consistent with 
PDR theory (Mobbs, et al., 2009; Mobbs, et al., 2007).  In these studies, participants are 
instructed to navigate a virtual maze and evade an approaching virtual predator.  If the 
predator catches the participant in the maze, the participant will receive noxious shock 
to the hand.  Functional MRI revealed that as the predator approached an inescapable 
distance from the participant, activation of the PAG and CeA occurred that correlated 
with post-imaging subjective results of dread (i.e., fear).  Furthermore, humans that 
received stimulation of sites within the defensive aggression circuit (dorsolateral 
periaqueductal gray, medial hypothalamus, amygdala) reported feelings of dread, 
anxiety, anger, fear, and impending death (Ervin, et al., 1969; Jenck, Moreau, & Martin, 
1995; Nashold, Wilson, & Slaughter, 1974; Tasker, 1982).  The forms of defensive 
responding, the environmental variables that determine the pattern of defensive 
behaviors, and the underlying neural circuit that generate defensive responding is highly 
conserved across mammalian species.   
As described above, the neural circuit that governs the execution of defensive 
responding to environmental threats is well characterized.  The medial hypothalamus 
and dlPAG are the core structures of the defense circuit and they are modulated by 
inputs from the amygdala (Siegel, 2005).  Environmental stimulus information (for 
example, sensory stimuli from a predator, such as a cat) enters the lateral amygdala of 
the rat via projections from the sensory thalamus and sensory cortex (LeDoux, 2007).  
The thalamic pathway to the amygdala is shorter and thus faster, but its capacity to 
represent a potentially threatening stimulus is limited (Bordi & LeDoux, 1994a, 1994b). 
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The thalamo-cortico-amygdala pathway, which involves several cortico-cortical links 
before reaching the amygdala (Romanski & LeDoux, 1993a, 1993b), is longer and 
slower, but provides detailed stimulus information about the threat.  The thalamic inputs 
thus may be useful for producing rapid defensive responses on the basis of limited 
stimulus information.  Rapid response to threats has obvious survival value (Ekman, 
1992; LeDoux, Cicchetti, Xagoraris, & Romanski, 1990; LeDoux, Iwata, Pearl, & Reis, 
1986; Ohman, 1986).  Cortical inputs permit subsequent detailed appraisal of the 
stimulus to determine whether in fact it is a threat and the need for continued defensive 
responding.  Sensory information from the lateral amygdala projects to the basolateral 
amygdala (BLA), and the BLA processes the affective salience of stimuli, including fear 
and other negative affective states associated with threatening stimuli (Davis & Whalen, 
2001; Rosen & Schulkin, 1998).  Threat stimuli-induced activation of the BLA activates 
projections to CeA, and CeA activation mediates the generation of defensive behaviors 
through its projections to the medial hypothalamus and the dlPAG.  These defensive 
behaviors have a phylogenetic history of enabling the individual to cope with threatening 
stimuli (Davis & Whalen, 2001).  Because exposure to a noxious stimulus represents an 
immediate and intimate threat, defensive behaviors activated under conditions of high 
predatory imminence are engaged.  The preeminence of noxious stimuli in engaging the 
defense circuit is indicated by the fact that noxious stimuli bypass the thalamus and 
cortex, and project directly to BLA and CeALC (Bernard & Besson, 1990; Burstein & 
Potrebic, 1993; Cliffer, et al., 1991; Gauriau & Bernard, 2002; Li & Neugebauer, 2004a; 
Newman, et al., 1996).   
 
50 
I propose that noxious and non-noxious threats are processed by a common 
neural substrate within CeALC to produce defensive responding, and that activation of 
CeM modulates this processing so to optimize the animal’s defense against 
environmental threats.  It is speculated that pain information from the spinal cord and 
threat stimulus information from the BLA converge upon the same neural population 
within CeALC, and this neural population is responsible for the activation of the dmVMH 
and dlPAG, and thereby promotes the execution of defensive responding to noxious 
and non-noxious threatening stimuli (see Figure 15).  As described earlier, the CeALC 
of the rat contains neurons that respond to noxious peripheral stimulation.  The CeA of 
the rat (along with the LA, BLA, dmVMH and dlPAG) also exhibits neuronal activation in 
response to non-noxious threatening stimuli.  Beckett and colleagues (1997) reported 
that exposure of naïve rats to 20 kHz ultrasonic tone increased Fos expression in all 
these sites (Beckett, Duxon, Aspley, & Marsden, 1997b).  That is, all components of the 
defense circuit are activated.  It is well documented that rats emit 22 kHz ultrasonic 
vocalizations (USV) when exposed to a predator (Blanchard, Blanchard, Rodgers, & 
Weiss, 1990; Knutson, Burgdorf, & Panksepp, 2002).  As the production of these calls is 
enhanced by the presence of familiar conspecifics (Blanchard, Blanchard, Agullana, & 
Weiss, 1991; Brudzynski & Ociepa, 1992), it has been suggested that they provide a 
warning signal about an imminent environmental threat.  Accordingly, these 
vocalizations (or 22 kHz pure tones) generate defensive responding in rats not directly 
exposed to a predator (Brudzynski & Chiu, 1995; Burgdorf, et al., 2008).  The defense 
circuit is particularly attuned to these vocalizations as a high proportion of neurons in LA 
and BLA respond preferentially to acoustic stimuli in the 18 – 27 kHz range (Bordi & 
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LeDoux, 1992).  Similarly, CeA, dlPAG and dmVMH exhibit enhanced Fos expression in 
rats following their exposure to cat odor (Dielenberg, et al., 2001).  The medial 
amygdaloid nucleus (MeA), but not LA and BLA, also exhibited increased Fos 
expression.  This latter finding is consistent with the fact that transmission of odor to 
CeA is via the MeA rather than LA and BLA.  MeA is considered the ‘vomeronasal 
amygdala', the principal limbic projection area of the accessory olfactory bulb (Kevetter 
& Winans, 1981; Luiten, Koolhaas, de Boer, & Koopmans, 1985; Martinez-Marcos & 
Halpern, 1999; Scalia & Winans, 1975).  Therefore, non-noxious threatening stimuli 
(auditory or olfactory), like noxious stimuli, appear to gain access to the core structures 
of the defense circuit via CeA.  The subdivisions of CeA that are activated by non-
noxious stimuli has not been evaluated but it is speculated that CeALC is the principal 
target of these stimuli. 
The notion that noxious and non-noxious threats are processed by a common 
neural substrate within CeALC to produce defensive responding, and that activation of 
CeM modulates this processing so to optimize the animal’s defense against 
environmental threats, may be explained by the Yerkes-Dodson theory of arousal and 
performance (Yerkes & Dodson, 1908).  This theory is illustrated with an inverted-U 
curve (see Figure 16), which indicates that as arousal increases, efficiency of 
performance increases until an optimum level of performance is achieved.  With 
increasing arousal past this optimum level, efficiency of performance decreases.  In the 
case of the rat and the predator cat, predator-stimulus specific information reaches the 
MeA (olfaction) and BLA (auditory and visual), which in turn sends excitatory projections 
to the CeALC.  In turn, the CeALC  dmVMH  dlPAG pathway is engaged and 
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defensive responses aimed at thwarting the predator are generated (see Figure 15, 
green pathway).  If the rat is injured during this confrontation, nociceptive information 
will project and add to the cellular activation within CeALC.  In terms of Yerkes-Dodson 
theory, this extreme compounded cellular activation would drive the rat’s defensive 
responding past optimum levels of performance and toward a decreased efficiency in 
performance, resulting in the inability for the rat to contend with the predator at optimum 
levels.  The rat’s behavior would be observed as a compound of defensive strategies to 
thwart the predator and strategies to tend to the injury.  Such a compound of behaviors 
would render the animal unable to devote attention solely to the predator.  This would 
serve in the predator’s favor because the animal would be unable to contend with the 
predator efficiently.   
In order to avoid this decreased efficiency in defensive responding to the 
predator, it is proposed that the CeALC engages a system that attenuates extreme 
levels of cellular arousal within CeALC.  As shown in Figure 15, when nociceptive 
projections add to the predator-induced cellular excitation of the CeALC, an intra-
amygdaloid projection from CeALC  CeM is recruited.  The CeM then engages the 
endogenous antinociceptive vlPAG serotonergic inhibitory projections that synapse 
upon CeALC and dmVMH neurons.  This inhibition attenuates the cellular excitation 
within the CeALC and dmVMH, and in terms of the Yerkes-Dodson theory, reverses the 
performance curve back toward optimum levels.  Thus, the rat is able to contend 
effectively with the predator via predator-specific defensive behaviors without 
concomitant generation of pain-related behaviors that would interfere with optimum 
performance.  Lastly, it is proposed that once the rat successfully fights off the predator, 
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or the rat is able to escape, the BLA-induced cellular activation of CeALC diminishes, 
the vlPAG serotonergic inhibition upon CeALC neurons releases, but the injury-induced 
cellular activation of CeALC remains and the rat will engage in pain-related defensive 
behaviors designed cope with the injury. 
 Evidence in support of this model includes studies that have examined the role of 
serotonin within the amygdala and medial hypothalamus on defensive aggression and 
pain behavior.  Systemic administration of the serotonin agonists buspirone and 
gepirone to wild rats significantly reduced defensive aggression (e.g., jump attacks, 
sonic vocalizations, biting; Blanchard, Rodgers, Hendrie, & Hori, 1988).  Studies on the 
anole lizard and mouse, bred for low or high levels of aggression, revealed that high 
aggression animals exhibit lower levels of serotonin within the amygdala (medial 
nucleus) and the medial hypothalamus (Serri & Ely, 1984; Summers, et al., 2005) and 
low aggression animals exhibit higher levels of serotonin within the amygdala (Young, et 
al., 2008).  Administration of serotonin into the rat cortical amygdala decreased 
defensive aggression measured as a decrease in the number of aggressive 
postures/attacks in the shock-induced fighting test (Pucilowski, Plaznik, & Kostowski, 
1985).  Lastly, injection of the serotonin agonist 8-OH-DPAT into the VMH suppressed 
defensive vocalizations in the cat elicited via electrical stimulation of the PAG 
(Hassanain, et al., 2003).  Studies have investigated the effect of intra-amygdaloid 
serotonin administration on pain responses, although no study to date has investigated 
this effect within the CeA.  Administration of serotonin into the BLA elevates tail-shock 
induced vocalization thresholds (Nandigama, 2005), and intra-basomedial amygdala 
serotonin administration increases the pressure required to elicit a vocalization in the tail 
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compression pain test (Plaznik, Danysz, & Kostowski, 1985).  Depletion of forebrain 
serotonin via severance of the medial forebrain bundle resulted in analgesia as 
measured via flinch-jump, stabilimetric, or hot-plate pain tests, which indicates forebrain 
serotonin attenuates pain-related behaviors (Harvey, Schlosberg, & Yunger, 1975).  
These studies suggest that increased levels of serotonin within the defensive circuit 
suppress defensive aggression and pain behaviors. 
4.5 Future Directions 
 The present study focused on the contribution of intra-CeA NMDA receptors to 
the suppression of pain affect. This manuscript put forth the notion that activation of 
CeM-NMDA receptors activate endogenous antinociceptive mechanisms via vlPAG mu-
opiate receptors.  Intra-vlPAG administration of CTAP effectively suppressed the 
elevations in VAD threshold generated by intra-CeA NMDA administration.  The present 
study did not assess the capacity of CTAP to alter intra-CeA APV elevations on VAD 
thresholds.  Given the proposition that APV inhibits nociceptive transmission at the level 
of CeALC-NMDA receptors, it is expected that intra-CeA APV-induced elevations in 
VADs would not be suppressed by intra-vlPAG CTAP administration.  This hypothesis is 
supported by the results from the present Fos study, which revealed that Fos levels 
within vlPAG are unchanged following intra-CeA APV treatment and indicates that the 
vlPAG is not involved in intra-CeA APV-induced elevations in vocalization thresholds. 
 The neurochemistry underlying nociceptive afferents to CeALC directly via the 
spinal cord and indirectly via the pontine parabrachial nucleus and intralaminar 
thalamus have yet to be investigated.  The present study and others (Li & Neugebauer, 
2004a, 2004b) provide evidence that intra-CeA NMDA receptors are implicated in the 
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transmission of nociception at the level of the CeALC, but it is not known whether 
glutamate is the primary neurotransmitter involved in these ascending projections.  In 
order to assess whether glutamate is the primary neurotransmitter involved in 
ascending nociception to the CeALC, immunocytochemistry studies could be 
performed.  A potential study may involve labeling of glutamate-containing nociceptive 
fibers to the CeA (e.g., spinoamygdaloid, spinoparabrachioamygdaloid, or 
spinothalamoamygdaloid fibers that respond to noxious stimulation) and receptor 
staining of glutamate receptors within CeALC.  Contacts of labeled fibers upon stained 
glutamate receptors would provide evidence that glutamate is the primary 
neurotransmitter involved in ascending nociception to CeALC.  It would also be of 
interest to assess whether BLA  CeALC projections that convey non-noxious threat 
information also utilize glutamate as the primary neurotransmitter. 
 In order to bolster the notion that pain information from the spinal cord and non-
noxious threat information from the BLA converge upon the same neural population 
within CeALC in order to produce affective responding via the CeA  dmVMH  dlPAG 
pathway, single unit recording of CeALC neurons may be evaluated.  One such study 
may investigate the evoked responses of CeALC neurons to noxious stimuli presented 
to the periphery and to non-noxious predator stimuli presented in the environment.  
Should a significant number of CeALC neurons respond to both noxious and non-
noxious stimuli, it may be concluded that these forms of threat information converge 
upon the same population of neurons within CeALC.   
 In addition, microdialysis may be used to measure levels of serotonin within 
CeALC and dmVMH following administration of NMDA into the CeA.  It is predicted that 
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following intra-CeA NMDA treatment, levels of serotonin within the CeALC and dmVMH 
would increase, reflecting engagement of the CeM  vlPAG circuit that provides 
serotonergic inhibition upon the CeALC and dmVMH.  Further, it is predicted that APV 
treatment of the CeA would not produce increases in serotonin levels in these structures 
because APV induced increases in vocalization thresholds is postulated to not rely upon 
a vlPAG serotonergic inhibition mechanism.   
 In terms of the ethological relevance of the present study, it is critical that the 
capacity for CeA-administered serotonin to alter pain behaviors and defensive 
aggression be evaluated.  As previously discussed, serotonin administration into several 
amygdaloid structures has been shown to suppress defensive responding and to 
suppress pain behaviors, yet these effects have not been demonstrated following 
serotonin administration into the CeA.  It would be possible to utilize the tail-shock 
vocalization response test and the microinjection technique to assess the capacity of 
intra-CeA serotonin to inhibit tail-shock induced vocalizations.  Additionally, it would be 
possible to use the microinjection technique to administer serotonin into the CeA and 
present the rat with a cat in an environment with limited escape routes so as to increase 
predatory imminence.  It is hypothesized that intra-CeA serotonin would inhibit pain 
affect in the form of VADs and inhibit defensive responding in response to the imminent 
predator cat.   
 The ability of intra-CeA serotonin to modulate NMDA-induced cellular excitation 
has yet to be evaluated.  Electrophysiology experiments may be used to record neural 
activity within the CeALC following application of NMDA to the CeALC.  It is predicted 
that administration of a serotonergic antagonist onto CeALC neurons would suppress 
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NMDA-induced neural activity.  It would follow that blockade of serotonergic inhibition of 
the CeALC and dmVMH would lead to the capacity of intra-CeA NMDA treatment to 
elicit defensive behaviors.  Thus, administration of a serotonin receptor antagonist to 
either CeALC, dmVMH, or both structures followed by intra-CeA NMDA administration 
should elicit VAD-like vocalizations and defensive aggression behaviors (e.g., rearing, 
biting, jump attacks).  With serotonergic receptors blocked, it is predicted that NMDA 
would be able to activate the dmVMH  dlPAG neural circuit responsible for the 
generation of defensive behaviors.      
 In summary, exploration of these future directions would provide strong support 
for the model presented here regarding the contribution of CeA-NMDA receptors to the 
generation of defensive behaviors in response to noxious and non-noxious stimuli.   
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 Figure 1. Mean (± S.E.M.) threshold current (mA) of spinal motor reflex, (SMR), 
vocalization during shock (VDS), and vocalization after-discharge (VAD) of rats who 
received bilateral vehicle (saline) and APV microinjections into the central nucleus of the 
amygdala (CeA). 
* = significantly elevated over vehicle (saline) treatment, p < .05 
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Figure 2. Mean (± S.E.M.) threshold current (mA) of spinal motor reflex, (SMR), 
vocalization during shock (VDS), and vocalization after-discharge (VAD) of rats who 
received bilateral saline and NMDA microinjections into the central nucleus of the 
amygdala (CeA). 
* = significantly elevated over saline treatment, p < .05 
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Figure 3. Schematic depicting the placement of cannulae for the NMDA anatomical 
control study.  Medial = 1.8mm medial to the central nucleus of the amygdala (CeA).  
Central = directly above the CeA.  Lateral = 1.8mm lateral to the CeA.  Each animal with 
a medial, central, or lateral cannula placement receives injections with (A) a 1.8mm 
injector, (B) a 3.0mm injector, and (C) a 4.2mm injector. 
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Figure 4. Distribution of injection sites within and around the central nucleus of the 
amygdala (CeA) that received bilateral injections of NMDA and saline. Black triangles 
indicate injection sites from the dose response study where bilateral 1µg NMDA 
produced vocalization threshold increases.  Black circles indicate injection sites from the 
anatomical control study where bilateral 1µg NMDA failed to produce vocalization 
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threshold increases (Other-NMDA).  Black squares indicate injection sites from the 
anatomical control study where bilateral 1µg NMDA produced vocalization threshold 
increases (CeA-NMDA).  Coordinates are millimeters posterior to bregma. Figures are 
adapted from The Rat Brain in Stereotaxic Coordinates by Paxinos and Watson (1998). 
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Figure 5. Comparison of the mean (± S.E.M.) threshold current (mA) of the spinal motor 
reflex, (SMR), vocalization during shock (VDS), and vocalization after-discharge (VAD) 
of rats produced by the bilateral administration of saline and 1µg NMDA into the CeA 
(CeA-NMDA) and sites surrounding the CeA (Other-NMDA).  
* = significantly elevated compared to saline treatment, p < .05 
† = significantly decreased compared to CeA – NMDA treatment, p < .05 
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Figure 6. Mean (± S.E.M.) threshold current (mA) of spinal motor reflex, (SMR), 
vocalization during shock (VDS), and vocalization after-discharge (VAD) of rats who 
received microinjections of saline or 0.025µg NMDA into the central nucleus of the 
amygdala (CeA) and saline or 0.25µg CTAP into the ventrolateral periaqueductal gray 
(vlPAG). 
* = significantly elevated over sal/CeA + sal/vlPAG, p < .05 
† = significantly decreased to NMDA/CeA + sal/vlPAG, p < .05. 
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Figure 7. Distribution of injection sites within (A) the ventrolateral periaqueductal gray 
(vlPAG) that received unilateral injections of 0.25µg CTAP and saline and (B) the 
central nucleus of the amygdala (CeA) that received bilateral injections of 0.025µg 
NMDA and saline.  Coordinates are millimeters posterior to bregma. Figures are 
adapted from The Rat Brain in Stereotaxic Coordinates by Paxinos and Watson (1998).
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Figure 8. Number of Fos-immunoreactive cells in the vlPAG following bilateral 
microinjection of saline, APV, or NMDA into the central nucleus of the amygdala (CeA).  
Data are expressed as mean±S.E.M. of Fos-positive neurons in a 400µm x 300µm area 
of tissue within the vlPAG. 
* = significantly elevated over saline, p < .05 
‡ = significantly elevated over 4µg APV, p < .05 
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Figure 9.  Representative vlPAG photomicrographs of Fos-immunoreactive cells (dark 
dots) from rats in the Fos expression Home Cage group and treated with bilateral 
microinjection of (A) saline, (B) 4µg APV, or (C) 1µg NMDA into the central nucleus of 
the amygdala (CeA).  Note the greater number of nuclei with dark stain in (C), but not in 
(A) or (B).  Sections on the left were photographed at 40x, and sections on the right 
were photographed at 200x. 
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 Figure 10. Comparison of the mean (± S.E.M.) threshold current (mA) of the spinal 
motor reflex, (SMR), vocalization during shock (VDS), and vocalization after-discharge 
(VAD) of rats produced by the bilateral administration of saline, 4µg APV, and 1µg 
NMDA into the CeA.  
* = significantly elevated compared to saline treatment, p < .05 
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Figure 11. Representative slices for qualitative analysis of the potential neurotoxic 
effects of NMDA administration into the central nucleus of the amygdala (CeA). (A) slice 
from a rat that received saline microinjections and (B) slice from a rat that received 1µg 
NMDA.  Note the lack of tissue blanching surrounding the CeA injection site in (B), 
indicating a lack of excitotoxicity. Slices at -1.88mm posterior to bregma. 
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Figure 12. Schematic representation of the internal circuitry of the ventrolateral 
periaqueductal gray (vlPAG). The vlPAG receives substance P (SP) efferents from the 
CeA that likely interact with enkephalin (ENK) neurons. Enkephalin release onto 
GABAergic interneurons releases tonic GABA inhibition on the serotonergic (5HT) 
projection neurons, resulting in disinhibition of serotonergic (5HT) projection neurons to 
limbic, thalamic, and brainstem sites that contribute to the suppression of pain affect 
elicited by morphine injected into vlPAG.  
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Figure 13. Schematic representation of the neurochemistry leading to inhibition of VAD 
responding in APV and NMDA treated rats.  APV likely blocks NMDA receptors within 
the CeALC, which directly blocks nociceptive transmission from the spinal cord at this 
level.  NMDA likely activates NMDA receptors within CeM.  CeM projections (likely 
utilizing substance P as a transmitter), activate vlPAG serotonergic projection neurons 
that synapse within CeALC to inhibit excitatory responses within this structure.  This 
mechanism likely prevents any action of NMDA on CeALC NMDA receptors.  
Additionally, vlPAG-serotonergic projection neurons synapse within dmVMH.  DmVMH 
and dlPAG together form the core structures responsible for the generation of VADs.  
Presumably, serotonin within dmVMH inhibits excitatory transmission to dlPAG, and 
thus VADs are not generated. 
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Figure 14.  Photograph of a rat engaged in defensive aggression behaviors in response 
to an imminent threat, a predator cat.  Note that the rat is cornered with limited escape 
routes, and the cat is proximal to the rat.  The rat is reared-up on its hind limbs and has 
its mouth open to bear its teeth and emit sonic vocalizations.  From Flynn, 1967. 
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Figure 15. Model of noxious and non-noxious input convergence within CeALC on the 
generation of defensive aggression.  Pain information from the spinal cord and threat 
stimulus information from the BLA converge upon the same neural population within 
CeALC.  This neural population is responsible for the activation of the dmVMH and 
dlPAG, which thereby promotes the execution of defensive responding to noxious and 
non-noxious threatening stimuli (circuit depicted in green).  Compound activation of the 
CeALC by noxious (e.g., tail-shock) and non-noxious (e.g., cat) stimuli results in the 
recruitment of an intra-CeM excitatory projection to vlPAG.  The vlPAG sends inhibitory 
serotonergic projections to the CeALC (and dmVMH) that attenuate the intra-CeALC 
cellular activation and allows the individual to perform defensive behaviors at an 
optimum level of performance. 
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Figure 16. Yerkes-Dodson Curve. As arousal increases, efficiency in performance 
increases until an optimum level of performance is achieved.  With increasing arousal 
past this optimum level, efficiency in performance decreases.  Based on Yerkes and 
Dodson, 1908. 
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APPENDIX B 
TABLES 
Table 1
Descriptive Statistics (Mean ± SEM) of SMR, VDS, and VAD Response Characteristics at Drug Treatment Threshold vs. Saline Threshold
SMR.RT SMR.AMP SMR.MAG VDS.RT VDS.AMP VDS.DUR VAD.RT VAD.AMP VAD.DUR
Latency (ms) Amplitude (mm) Magnitude (cm x ms) Latency (ms) Amplitude (dB) Duration (ms) Latency (ms) Amplitude (dB) Duration (ms)
NMDA Dose Response & Anatomical Control Studies
saline 309.20 ± 39.79 16.03 ± 2.38 115.02 ± 16.42 295.05 ± 20.58 90.06 ± 0.94 558.20 ± 22.89 1211.50 ± 32.34 86.99 ± 0.79 657.20 ± 55.46
.1µg NMDA 248.86 ± 96.09 27.14 ± 4.59 168.40 ± 51.75 286.29 ± 84.89 87.26 ± 1.97 392.29 ± 81.53 1114.86 ± 12.86 92.41 ± 2.24 747.71 ± 138.11
.25µg NMDA 286.57 ± 85.71 17.87 ± 5.98 97.07 ± 38.98 206.86 ± 53.39 84.70 ± 1.06 310.29 ± 44.09 1523.60 ± 294.04 89.96 ± 2.74 541.20 ± 176.14
.5µg NMDA 400.80 ± 93.88 18.80 ± 8.32 111.54 ± 36.91 255.00 ± 120.21 86.53 ± 1.71 334.50 ± 57.42 1102.00 ± 0.00 87.30 ± 3.20 312.00 ± 20.00
1µg NMDA 303.44 ± 50.95 19.90 ± 3.54 113.37 ± 19.06 223.18 ± 26.39 85.52 ± 1.22 408.45 ± 43.66 1287.14 ± 59.99 88.42 ± 1.39 606.67 ± 74.88
CeA - vlPAG Interaction Study
saline CeA + saline vlPAG 369.71 ± 108.48 14.59 ± 5.06 111.46 ± 39.07 265.43 ± 26.19 89.81 ± 2.80 510.00 ± 69.80 1102.00 ± 0.00 87.30 ± 2.59 541.43 ± 106.30
0.025µg NMDA CeA + saline vlPAG 239.75 ± 77.98 26.30 ± 4.61 223.73 ± 56.76 229.25 ± 52.38 90.53 ± 2.62 438.50 ± 72.63 1351.75 ± 94.85 89.76 ± 1.69 685.00 ± 77.62
saline CeA + 0.25µg CTAP vlPAG 179.00 ± 32.75 18.36 ± 5.71 131.49 ± 43.22 256.75 ± 52.37 92.89 ± 2.02 593.25 ± 57.10 1239.00 ± 102.45 87.45 ± 2.41 726.38 ± 169.70
0.025µg NMDA CeA + 0.25µg CTAP vlPAG 201.00 ± 47.85 19.01 ± 7.61 141.05 ± 53.42 266.75 ± 38.53 89.34 ± 2.51 432.00 ± 76.39 1379.50 ± 148.50 87.20 ± 1.02 630.00 ± 111.99
Fos Expression Study - Shock Group
saline 306.00 ± 119.41 25.25 ± 7.83 202.85 ± 69.59 247.00 ± 63.43 89.98 ± 0.54 476.50 ± 99.49 1104.00 ± 2.00 89.23 ± 4.67 727.50 ± 231.00
4µg APV 254.50 ± 98.13 38.68 ± 13.20 231.75 ± 95.61 118.50 ± 14.57 90.90 ± 3.70 425.00 ± 65.59 1123.33 ± 21.33 97.90 ± 1.67 347.33 ± 97.24
1µg NMDA 292.00 ± 132.93 22.15 ± 12.06 70.35 ± 22.19 92.00* 92.70* 388.00* ---** ---** ---**
* = mean is based on n = 1, see text for details
** = n is equal to zero, see text for details
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Table 2
Treatment for which Dunnet's
Characteristic F df p is significant
SMR.RT 0.29 4, 83 0.89 --
SMR.AMP 0.81 4, 83 0.53 --
SMR.MAG 0.51 4, 83 0.73 --
VDS.RT 1.21 4, 79 0.31 --
VDS.AMP 3.18 4, 79 0.02* 1μg NMDA/side
VDS.DUR 6.16 4, 79 0.00* 0.25μg NMDA/side
0.5μg NMDA/side
1μg NMDA/side
VAD.RT 2.26 4, 74 0.07 --
VAD.AMP 1.62 4, 74 0.18 --
VAD.DUR 0.77 4, 74 0.55 --
SMR.RT 1.40 3, 30 0.26 --
SMR.AMP 0.67 3, 30 0.58 --
SMR.MAG 1.01 3, 30 0.41 --
VDS.RT 0.15 3, 30 0.93 --
VDS.AMP 0.41 3, 30 0.75 --
VDS.DUR 1.21 3, 30 0.32 --
VAD.RT 1.37 3, 30 0.27 --
VAD.AMP 0.39 3, 30 0.76 --
VAD.DUR 0.41 3, 30 0.75 --
FOS Expression Study -  Shock Group
SMR.RT 0.05 2, 11 0.95 --
SMR.AMP 0.61 2, 11 0.57 --
SMR.MAG 1.54 2, 11 0.27 --
VDS.RT 2.38 2, 8 0.18 --
VDS.AMP 0.11 2, 8 0.9 --
VDS.DUR 0.16 2, 8 0.86 --
VAD.RT 1.15 1,6 0.33 --
VAD.AMP 2.32 1,6 0.19 --
VAD.DUR 1.78 1,6 0.24 --
* p < .05
CeA - vlPAG Interaction Study 
SMR, VDS, and VAD Response Characteristics at Drug Treatment Thershold vs.
Saline Threshold: ANOVA and Tukey's HSD
NMDA Dose Response and Anatomical Control Studies
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The amygdala processes stimuli that threaten an individual and organizes the 
execution of affective behaviors designed to cope with the threat.  The prototypical 
threat to an individual is exposure to a noxious stimulus. The central nucleus of the 
amygdala (CeA) receives nociceptive afferents and exhibits neuronal activation in 
response to noxious peripheral stimulation.  NMDA receptors within CeA mediate this 
noxious-evoked neural excitation, and previous studies in the laboratory have shown 
that blockade of CeA NMDA receptors via the antagonist APV elevates the threshold for 
noxious tail-shock-induced vocalization afterdischarges (VADs), a validated measure of 
pain affect in the rat.  The present study further evaluated the contribution of NMDA 
receptors to the suppression of pain affect. 
Intra-CeA NMDA receptor activation via the agonist NMDA elevated VAD thresholds 
in a dose dependent manner.  That the NMDA receptor agonist and antagonist produce 
similar behavioral effects is hypothesized as the result of targeting separate neural 
populations within the CeA.  Whereas the antagonist likely inhibits nociception at the 
level of the lateral capsular division of the CeA, the agonist likely activates 
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antinociceptive efferents at the level of the vlPAG.  In support of this hypothesis, the 
present study revealed that Fos expression within vlPAG is greater in rats that received 
intra-CeA agonist NMDA treatment compared to those that received the antagonist APV 
or saline.  Lastly, intra-CeA NMDA agonist-induced elevations in VAD thresholds were 
blocked via the pre-treatment of the vlPAG with the mu-opiate antagonist CTAP.  These 
studies provide the first demonstration of the contribution of CeA NMDA receptors to the 
generation of pain affect in the rat. 
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